HER3 radioimmunotherapeutic agents for the treatment of solid tumors

JP2023550462A5Active Publication Date: 2024-11-29ACTINIUM PHARMACEUTICALS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023530591
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-10-22
Filing Date
2021-11-22
Publication Date
2024-11-29
Estimated Expiration
2041-11-22

AI Technical Summary

Technical Problem

Current therapies for HER3-positive cancers are insufficient, and there is a need for more effective methods to target and treat these cancers, particularly solid tumors, by modulating HER3-mediated signaling.

Method used

The use of radiolabeled HER3-targeted drugs, such as monoclonal antibodies, peptides, or small molecules, which deliver ionizing radiation to HER3-positive cells, potentially combined with additional therapeutic agents like immune checkpoint inhibitors or DNA damage response inhibitors, to enhance treatment efficacy.

Benefits of technology

The radiolabeled HER3-targeted drugs effectively kill HER3-positive cancer cells by inducing DNA damage and can be administered in patient-specific doses to optimize treatment outcomes without causing harmful downregulation of HER3 receptors, offering improved tumor targeting and killing.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000052_0000
    Figure 00000052_0000
  • Figure 00000053_0000
    Figure 00000053_0000
  • Figure 00000053_0001
    Figure 00000053_0001
Patent Text Reader

Abstract

Radionuclides, e.g. 225 Ac, 177 Lu, 131 I, 90 Y, 213 Bi, 211 At, 213 Bi, 227 Th, or 212 Compositions and methods are provided for treating solid cancers, such as HER3-positive tumors, in a subject by administering an effective amount of a Pb-labeled HER3-targeted drug, alone or in combination with other therapeutic agents or modalities. The effective amount of the radiolabeled HER3-targeted drug can be the maximum tolerated dose administered as a single bolus or in divided doses totaling the maximum tolerated dose.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] Cross-reference of related applications This application claims priority to International Application PCT / US21 / 56259 filed on 22 October 2021, and its priority application, U.S. Provisional Application No. 63 / 250,725 filed on 30 September 2021, and U.S. Provisional Patent Application No. 63 / 226,699 filed on 28 July 2021, respectively; U.S. Provisional Patent Application No. 63 / 118,181 filed on 25 November 2020; and U.S. Provisional Patent Application No. 63 / 116,225 filed on 20 November 2020, each of which is incorporated herein by reference in its entirety. Sequence List This application includes an electronically submitted sequence listing in ASCII format, which is incorporated herein by reference in its entirety. The ASCII copy, created on November 22, 2021, is named ATNM-010PCT_SL_ST25.txt and has a size of 191,107 bytes. The present invention relates to the field of radiation therapy. [Background technology]

[0002] ErbB3 / HER3 is a type I transmembrane glycoprotein that is a member of the erythroblastic oncogene B (ErbB) family of tyrosine kinase receptors (EGFR, HER2, HER3, and HER4). HER3-mediated signaling can be activated in a ligand-dependent or ligand-independent manner. In the absence of a ligand, the HER3 receptor molecule is usually expressed on the cell surface as a monomer with a structure that prevents receptor dimerization. In this structure, the dimerization loop of subdomain II is in intramolecular contact with the pocket of subdomain IV. When HER3 ligands such as neuregulins (NRGs), e.g., NRG1 (also known as heregulin or HRG) or NRG2, bind to subdomains I and III of the extracellular region, a structural change occurs, exposing the dimerization loop of subdomain II, thereby promoting receptor dimerization and signaling. Certain cancer-associated mutations in HER3 disrupt this interaction between subdomains II and IV, the interaction necessary for the formation of an inactive "closed" structure, thereby leading to the constitutive presentation of the dimerization loop and activation of HER3-mediated signaling in the absence of ligand binding. Antibodies targeting HER3 can be used to target specific cancer cells, particularly certain solid tumors. HER3 is overexpressed in several cancer types, including breast cancer, gastrointestinal cancer, and pancreatic cancer. A correlation has been shown between HER2 / HER3 expression and the progression of these cancers from the non-invasive to the invasive stage. Drugs that inhibit HER3-mediated signaling, such as anti-HER3 antibodies, may enable the construction of a robust immune response against cancer cells, which is usually insufficient with conventional therapeutics. Accordingly, one object of the present invention disclosed herein is to provide a therapeutically effective radiolabeled HER3-targeted drug, such as for the treatment of HER3-positive cancer. A related object of the present invention disclosed herein is to provide a therapeutic method comprising administering such a radiolabeled HER3-targeted drug alone or in combination with one or more additional therapeutic agents. [Overview of the project]

[0003] The present invention provides a method for diagnosing and / or treating HER3-positive (HER3-expressing) cancer using a HER3-targeting drug such as a monoclonal antibody, peptide, or small molecule labeled with a radioisotope, and the radiolabeled HER3-targeting drug. According to certain embodiments of the present invention, a radiolabeled HER3-targeting drug useful for diagnostic purposes is 111 In, 68 Ga, 64 Cu, 89 Zr, or 177 an anti-HER3 antibody, peptide, or small molecule containing a radioisotope such as Lu. According to certain other embodiments, a radiolabeled HER3-targeting drug useful for therapeutic intervention can be an anti-HER3 antibody, peptide, or small molecule containing a radioisotope such as: 131 I, 125 I, 123 I, 90 Y, 177 Lu, 186 Re, 188 Re, 89 Sr, 153 Sm, 32 P, 225 Ac, 213 Bi, 213 Po, [[ID=4l]] 211 At, 212 Bi, 213 Bi, 223 Ra, 227 Th, 149 Tb, 137 Cs, 212 Pb, or a combination thereof. According to certain preferred embodiments, the radiolabeled HER3-targeting drug can contain 131 I, 90 Y, 177 Lu, 225 Ac, 213 Bi, 211 At, 227 Th, or 212 Pb.

[0004] According to certain embodiments, the HER3-positive cancer can be a solid tumor. The therapeutic methods of the present invention disclosed herein generally involve administering a therapeutically effective dose of a radiolabeled HER3-targeted drug to a patient. Depending on a particular embodiment, the effective dose of the radiolabeled HER3-targeted drug may be the maximum tolerated dose (MTD) or a divided dose, wherein the total amount of radiation administered in divided doses is the MTD. In a particular embodiment, a composition or amount of a HER3-targeted drug comprising a radiolabeled portion and a non-radiolabeled portion of the HER3-targeted drug is provided and / or used. Therefore, the effective dose of the HER3-targeted drug may include a total protein dose of less than 100 mg, e.g., 5-60 mg or 5-45 mg. In a particular embodiment, the total protein dose may be 0.001-3 mg / kg of body weight, e.g., 0.005-2 mg / kg of body weight. In a particular embodiment, the total protein dose may be less than 2 mg / kg, or less than 1 mg / kg, or less than 0.5 mg / kg, or less than 0.1 mg / kg. A portion of the total protein dose is radiolabeled (i.e., radioconjugated) as described, and the effective dose of the radiolabeled HER3-targeted drug may vary depending on the specific radioisotope selected. Preferred radioisotopes for therapeutic intervention are: 225 Ac, 177 Lu, 131 I, 90 Y, 213 Bi, 211 At, 227 Th, or 212 It contains Pb. Therefore, HER3-targeted drugs may contain a radiolabeled portion and an unlabeled portion.

[0005] In accordance with a particular aspect, the effective amount of HER3-targeted drugs in terms of radiation dose, i.e., these radiolabeled portions, for example 225 The effective amount of Ac anti-HER3 antibody, peptide, or small molecule may include doses of 0.1 to 20 μCi / kg of target body weight, for example, 0.1 to 10 μCi / kg, or 0.1 to 5 μCi / kg of target body weight, or 0.5 to 20 μCi / kg, or 1 to 10 μCi / kg of target body weight. According to a particular aspect, the effective amount of HER3-targeted drugs, i.e., these radiolabeled portions, for example 225The effective amount of Ac anti-HER3 antibody, peptide, or small molecule may vary depending on the structure of the target drug, i.e., a full-length antibody or antigen-binding antibody fragment (e.g., Fab, Fab2, minibody, nanobody, etc.) as disclosed herein. For example, if the HER3 target drug is a full-length antibody. 225 If it contains an Ac anti-HER3 antibody, the dose may be less than 5 μCi / kg of body weight, for example, 0.1 to 5 μCi / kg of body weight. Alternatively, the HER3-targeted drug may be a fragment. 225 When containing Ac anti-HER3 antibody, the dose may be greater than 5 μCi / kg target body weight, for example, 5-20 μCi / kg target body weight.

[0006] In a particular embodiment, HER3-targeted drugs bind to HER3 epitopes recognized by anti-HER3 antibodies, such as monoclonal antibodies or antigen-binding fragments thereof, such as IgG or antigen-binding fragments thereof, such as patritumab from Daiichi Sankyo, cerivanthumab (MM-121) from Merrimack Pharmaceuticals, lumuretuzumab from Roche, elgemtumab from Novartis, GSK2849330 from GlaxoSmithKline, CDX-3379 from Celldex Therapeutics, EV20 and MP-RM-1 from MediPharma, ISU104 from Isu Abxis Co., HMBD-001 (10D1F) from Hummingbird Bioscience Pte., REGN1400 from Regeneron Pharmaceuticals, and / or AV-203 from AVEO Oncology. In a particular manner, the anti-HER3 antibody is selected from one or more of the following: patritumab, cerivanthumab, lumuretuzumab, elgemtumab, AV-203, CDX-3379, or GSK2849330. In a particular manner, HER3-targeted drugs may be administered over the course of treatment according to a dosing schedule selected from the group consisting of administration once every 7, 10, 12, 14, 20, 24, 28, 35, and 42 days, including at least two doses during the course of treatment. In a particular manner, HER3-targeted drugs may be administered according to a dosing schedule that includes two doses, such as on day 1 and on days 5, 6, 7, 8, 9, or 10 of the treatment period, or on day 1 and day 8 of the treatment period. In a particular manner, HER3-targeted drugs may be administered as a single bolus or infusion in a target-specific single dose.

[0007] In particular embodiments, the method may further include the administration of one or more additional therapeutic agents, such as chemotherapeutic agents, small molecule drugs, anti-inflammatory agents, immunosuppressants, immunomodulators, antimyeloma drugs, cytokines, or combinations thereof. Exemplary chemotherapeutic agents include at least radiosensitizers that may exhibit synergistic effects with radiolabeled HER3-targeted agents, such as temozolomide, cisplatin, and / or fluorouracil. In particular embodiments, the method may further include the administration of one or more immune checkpoint therapeutics. Exemplary immune checkpoint therapeutics include antibodies against CTLA-4, PD-1, TIM-3, VISTA, BTLA, LAG-3, TIGIT, CD28, OX40, GITR, CD137, CD40, CD40L, CD27, HVEM, PD-L1, PD-L2, PD-L3, PD-L4, CD80, CD86, CD137-L, GITR-L, CD226, B7-H3, B7-H4, BTLA, TIGIT, GALS, KIR, 2B4, CD160, CGEN-15049, or any combination thereof. In particular embodiments, the immune checkpoint therapeutic may include antibodies against immune checkpoint proteins selected from the group consisting of antibodies against PD-1, PD-L1, PD-L2, CTLA-4, CD137, and combinations thereof. In accordance with a particular aspect, immune checkpoint therapeutic agents may be administered to a subject in an effective dose, for example, 0.1 to 50 mg / kg patient body weight, or 0.1 to 5 mg / kg or 5 to 30 mg / kg.

[0008] In particular embodiments, the method may further include the administration of one or more DNA damage response inhibitors (DDRi). Exemplary DDRi include one or more antibodies or small molecules targeting poly(ADP-ribose) polymerase (i.e., poly(ADP-ribose) polymerase inhibitors or PARPi). PARPi may include, for example, olaparib, niraparib, lucaparib, talazoparib, or any combination thereof. In particular embodiments, PARPi may be provided in a target effective dose containing 0.1 to 1200 mg / day, for example, 0.100 to 600 mg / day or 0.25 to 1 mg / day. Exemplary effective doses include 0.1 mg, 0.25 mg, 0.5 mg, 0.75 mg, 1.0 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 700 mg, 750 mg, 800 mg, 900 mg, and 1000 mg, administered orally once or twice daily. Other exemplary DDRi include inhibitors of ataxia telangiectasia mutations (ATM), ataxia talangiectasia mutated, and Rad3-related mutations (ATR), or Wee1. Exemplary inhibitors of ATM include KU-55933, KU-59403, woltmannin, CP466722, and KU-60019. Exemplary inhibitors of ATR include at least schizandrine B, NU6027, NVP-BEA235, VE-821, VE-822, AZ20, and AZD6738. Exemplary inhibitors of Wee1 include AZD-1775 (i.e., adavocertib).

[0009] In a particular embodiment, the method may further include the administration of one or more CD47 blockers. The CD47 blockers may include monoclonal antibodies, SIRPα-Fc fusion proteins, or other molecules that prevent CD47 from binding to SIRPα or otherwise downregulate the immunosuppressive activity of CD47, such as maglorimab, remzopalimab, AO-176, AK117, IMC-002, IBI-188, IBI-322, BI766063, ZL-1201, AXL148, RRx-001, ES004, SRF231, SHR-1603, TJC4, TTI-621, or TTI-622. Exemplary effective doses of CD47 blockers include 0.05–5 mg / kg patient body weight. CD47 blockers may also include agents that modulate the expression of CD47 and / or SIRPα, such as nucleic acid approaches including antisense, RNAi, or μRNA approaches. Exemplary CD47 blockers also include phosphorodiamidate morpholino oligomers (PMOs) that inhibit the translation of CD47, such as MBT-001. In a particular embodiment, the method may further include the administration of a combination of further therapeutic agents. Exemplary combinations include at least one or more DDRi and / or one or more immune checkpoint therapeutics and / or one or more CD47 blockers and / or one or more chemotherapeutic agents and / or one or more small molecule anticancer agents and / or one or more targeted agents for various cancer-associated antigens.

[0010] Depending on the specific embodiment, radiolabeled HER3-targeted drugs and one or more additional therapeutic agents may be administered simultaneously or sequentially. If two or more additional therapeutic agents are administered, these drugs may be administered simultaneously or sequentially. In particular aspects of the present invention, the radiolabeled HER3-targeted drug may be a multispecific targeted drug in which at least one portion recognizes HER3, such as a multispecific antibody or a bispecific antibody. Accordingly, the method may include administering an effective amount of the multispecific antibody to a target, the multispecific antibody comprising: a first target recognition component that specifically binds to an epitope of HER3; and a second target recognition component that specifically binds to an epitope of HER3 different from the first target recognition component, or to an epitope of a different antigen, such as a different cancer-associated antigen. In particular aspects, the HER3-targeted drug is a multispecific antibody against a first epitope of HER3 and at least a second epitope of HER3, or against HER3 and at least a second (different) antigen. Examples of polyspecific antibodies that may be radiolabeled for diagnostic and / or therapeutic use according to the present invention include: anti-HER3 / HER2 antibodies such as MM-111 from Merrimack Pharmaceuticals or MCLA-128 from Merus NV; anti-IGF-1R / HER3 antibodies such as MM-141 (i.e., istilatumab) from Merrimack Pharmaceuticals; anti-EGFR / HER3 antibodies such as MEHD7945A (i.e., durigotumab) from Roche; or cetuximab-based bispecific or polyspecific Zybodies from Zyngenia Inc.

[0011] A composition is provided, according to a particular embodiment, comprising a mixture of a HER3-targeted drug, such as an antibody against HER3, and one or more further targeted drugs, such as antibodies targeting or against one or more different cancer-associated antigens, wherein one or more of the HER3-targeted drug and other targeted drugs may or may not be radiolabeled in any combination. An exemplary antibody composition comprising the antibody mixture is Symphogen's Sym013, which has at least six monoclonal antibodies against EGFR (HER1), HER2, and HER3. In one embodiment, one or more of the antibodies in Sym013 may be radiolabeled in any combination of at least one HER3 antibody and one or more antibodies against EGFR and HER2, or none of them. Further features, advantages, and aspects of the present invention may be shown or become apparent by considering the following detailed description, the drawings in some cases, and the claims. Furthermore, it should be understood that both the above summary of the invention and the following detailed description are illustrative and intended to provide further explanation without limiting the scope of the claimed invention. [Brief explanation of the drawing]

[0012] [Figure 1] This figure shows the amino acid sequences of the N-terminal region, complementarity-determining region, and variable region of the heavy and light chains of a HER3 monoclonal antibody that can be embodied in various embodiments of the present invention. [Figure 2] This figure shows the full-length heavy chain and light chain amino acid sequences, with and without the leader sequence, of HER3 monoclonal antibodies that can be embodied in various embodiments of the present invention. [Figure 3] This graph shows the binding characteristics of an Ac225-labeled DOTA-conjugated anti-HER3 monoclonal antibody compared to an unmodified anti-HER3 antibody and a nonspecific antibody (IgG) using an ELISA assay, demonstrating that modifications do not substantially affect the immunoreactivity to HER3. [Figure 4] This graph shows the results of a flow cytometry assay examining the binding of 225Ac-HER3-ARC, an unmodified anti-HER3 mAb, a nonspecific antibody control (IgG), and a secondary antibody-only control to HER3-positive NCI-H1975 cells (human lung adenocarcinoma, NSCLC) and BxPC-3 cells (human pancreatic adenocarcinoma). [Figure 5] This graph shows the in vitro cytotoxic effect of 225Ac-HER3-ARC on the HER3-positive cell line NCI-H1975 as a function of radiation dose. [Figure 6A] This graph shows that 225Ac-HER3-ARC upregulates cell surface calreticulin (CRT) in NCI-H1975 cells. [Figure 6B]This graph shows that 225Ac-HER3-ARC upregulates CD47 on NCI-H1975 cells. [Figure 7A] This graph shows the results of a phagocytic assay demonstrating that the combination of 225Ac-HER3-ARC and an anti-CD47 blocking antibody enhanced the phagocytic activity of BxPC-3 cells compared to either treatment alone. [Figure 7B] This graph shows the results of a phagocytosis assay demonstrating that the combination of 225Ac-HER3-ARC and an anti-CD47 blocking antibody enhanced the phagocytic activity of NCI-H1975 cells compared to either treatment alone. [Figure 8] This graph shows the effects of 225Ac-HER3-ARC, at various radiation doses and in combination with anti-CD47 blocking antibodies, on tumor growth in a mouse xenograft model of human tumor (NCI-H1975 cells). [Figure 9] Figure 8 is a graph showing the weight of the subjects in the experiment over time. [Figure 10] Figure 8 is a graph showing the survival rate over time in the experimental control group of the experiment described. [Figure 11] This graph compares the effects on tumor growth of the vehicle (control), CD47 blocking antibody maglorimab alone, 225Ac trastuzumab alone, and maglorimab and 225Ac trastuzumab in combination in an NGS mouse xenograft model using the HER2-positive SK-OV3 human ovarian cancer cell line. [Figure 12] This graph compares the effects on tumor growth of the vehicle (control), maglorimab monotherapy, 177Lu trastuzumab monotherapy, and maglorimab and 177Lu trastuzumab combination therapy in an NGS mouse xenograft model using the SK-OV3 human ovarian cancer cell line. [Modes for carrying out the invention]

[0013] In one embodiment, the present invention, as disclosed herein, provides compositions and methods for treating HER3-expressing cancer, i.e., HER3-positive cancer. This embodiment generally involves administering an effective amount of a radiolabeled HER3-targeted drug, such as a HER3-targeting radiolabeled antibody, peptide, or small molecule, alone or in combination with one or more additional therapeutic agents and / or modes of treatment / treatments, to a mammalian subject in need of treatment, such as a human patient. Additional therapeutic agents and modes of treatment that may be used include, for example, at least one or more immune checkpoint therapeutic agents, and / or inhibitors of one or more components of the DNA damage response pathway (i.e., one or more agents against DNA damage response inhibitors (DDRi), e.g., poly(ADP-ribose) polymerase, i.e., PARPi), and / or one or more chemotherapeutic agents such as one or more CD47 / SIRPα-axis blockers and / or radiosensitizers, and / or one or more small molecule antitumor agents such as tyrosine kinase inhibitors, and / or one or more targeted agents against various antigens. The present invention disclosed herein further provides methods for identifying, imaging, and / or diagnosing HER3-positive cancers in a subject. The present invention disclosed herein further provides methods for treating subjects after identifying, imaging, and / or diagnosing HER3-positive cancers in a subject, according to any of the methods disclosed herein.

[0014] Definitions and Abbreviations The singular forms "a," "an," and "the" include plural references unless explicitly stated otherwise in the context. Therefore, for example, the reference to "an antibody" includes both a single antibody and multiple different antibodies. The terms “includes” and the forms of “includes” used herein and in the claims, as well as the terms “incorporates” and the forms of “incorporates,” are not limited to the incorporation of elements other than those referred to herein. Furthermore, throughout this disclosure, these various aspects or elements are described in terms of “incorporates” or “includes,” but the corresponding aspects or elements described in terms of “essentially consisting of” or “consisting of” are also disclosed. For example, while certain aspects of the Invention are described in terms of a method that “incorporates” or “includes” administering a radiolabeled targeted drug, the corresponding methods described instead as “essentially consisting of” or “consisting of” administering a radiolabeled targeted drug are also within the scope of the aforementioned aspects and are disclosed herein. In this disclosure, when the term “approximately” is used in relation to numerical representations or values, for example, in descriptions of temperature, time, quantity, and concentration, including descriptions of ranges, it refers to a variation of ±10% and a variation of ±5% or ±1% of the numerical representation or value within a larger variation.

[0015] As used herein in relation to targeted drugs such as antibodies, antibody fragments, Fab fragments, or aptamers, “administer” means to deliver the drug to the body of the target by any known method suitable for antibody delivery. Specific methods of administration include, but are not limited to, intravenous, transdermal, subcutaneous, intraperitoneal, intrathecal, and intratumoral administration. Exemplary methods of antibody administration may substantially be those described in International Publication 2016 / 187514, which is incorporated herein by reference. Furthermore, in the present invention, antibodies may be formulated using, for example, one or more routinely used and pharmaceutically acceptable carriers and excipients. Such carriers and excipients are well known to those skilled in the art. For example, injectable delivery systems may include solutions, suspensions, gels, microparticles, and polymeric injectables, and may contain excipients such as solubility modifiers (e.g., ethanol, propylene glycol, and sucrose) and polymers (e.g., polycaprylactone and PLGA).

[0016] As used herein, the term “antibody” includes, but is not limited to: (a) immunoglobulin molecules comprising two heavy chains and two light chains that recognize antigens; (b) polyclonal and monoclonal immunoglobulin molecules; (c) monovalent and bivalent fragments thereof, e.g., Fab, di-Fab, scFvs, bispecific antibodies, minibodies, and nanobodies (sdAb); (d) spontaneously occurring and non-spontaneously occurring antibodies, e.g., fully synthetic antibodies, IgG-Fc-silent, and chimeras; and (e) bispecific and polyspecific forms thereof. Immunoglobulin molecules may originate from any of the generally known classes, including but not limited to IgA, secretory IgA, IgG, and IgM. Subclasses of IgG are also well known to those skilled in the art, including but not limited to human IgG1, IgG2, IgG3, and IgG4. The N-terminus of each chain determines a “variable region” of about 100 to 110 or more amino acids, primarily involved in antigen recognition. The terms variable light chain (VL) and variable heavy chain (VH) refer to these regions of the light chain and heavy chain, respectively. Antibodies may be human, humanized, or non-human antibodies. In certain aspects of the invention disclosed herein, when "antibody" is referred to or written as "antibody," it is assumed to refer to either the full-length antibodies disclosed herein or any fragment thereof, unless expressly otherwise indicated. A "humanized" antibody refers to an antibody in which some, most, or all of the amino acids outside the CDR domain of a non-human antibody are replaced with corresponding amino acids derived from human immunoglobulin. In one embodiment of the humanized form of an antibody, some, most, or all of the amino acids outside the CDR domain are replaced with amino acids from human immunoglobulin, while some, most, or all of the amino acids within one or more CDR regions remain unchanged. Minor additions, deletions, insertions, substitutions, or modifications of amino acids are acceptable as long as they do not impair the antibody's ability to bind to a particular antigen. Humanized antibodies retain similar antigen specificity to the original antibody. A "chimeric antibody" refers to an antibody in which the variable region originates from one species and the constant region originates from another species, such as an antibody in which the variable region originates from a mouse antibody and the constant region originates from a human antibody.

[0017] A "complementarity-determining region" or "CDR" collectively refers to the amino acid sequence that determines the binding affinity and specificity of the variable region of the innate immunoglobulin binding site. There are three CDRs in both the light chain and the heavy chain of an antibody. A "framework region" or "FR" refers to a typically conserved amino acid sequence that intervenes between CDRs and functions as a scaffold between them. The "constant region" refers to the portion of an antibody molecule where the antibody class does not change, and is defined by the types of light and heavy chains. For example, the light chain constant region can be of the κ or λ type, and the heavy chain constant region can be one of the five chain isotypes: α, δ, ε, γ, or μ. This constant region can generally confer the effector function exhibited by the antibody. Various subclasses of heavy chains (such as the IgG subclass of the heavy chain) are primarily responsible for different effector functions. The HER3-targeted drugs used herein may be antibodies as defined herein, such as full-length antibodies, minibodies, or nanobodies, that bind to any available epitope of HER3, such as human HER3, and have high immunoreactivity.

[0018] As used herein, “immunoreactivity” refers to the degree of an immunoglobulin’s ability to recognize and bind to a specific antigen. “Specific binding,” “specifically binding,” or “binding” refers to an antibody binding to an antigen or an epitope within an antigen with higher affinity than other antigens, within a suitable context, such as the body of a mammalian subject, such as a human patient. Antibodies that can be embodied or used in various embodiments of the present invention include, for example, about 1 × 10⁻⁶ antibodies. -8 Less than M, for example, approximately 1 × 10 -9 M or less, approximately 1×10 -10 M or less, approximately 1×10 -11 M or less, or approximately 1 × 10 -12 Equilibrium dissociation constants (K) less than or equal to M D ) And normally, K binds to nonspecific antigens (e.g., BSA, casein). D K at least 1 / 100th of DThe antibody binds to the antigen or an epitope within the antigen. The dissociation constant can be measured using standard procedures. However, antibodies that specifically bind to an antigen or an epitope within an antigen may cross-react with other related antigens and with the same antigen in other species (homologous organisms), such as humans or monkeys, e.g., Macaca fascicularis (cynomolgus monkey, cyno), Pan troglodytes (chimpanzee, chimp), or Callitrisrix jacchus (common marmoset, marmoset). An "epitope" refers to a site on a target molecule (e.g., at least a portion of an antigen) that a targeted drug, such as an antibody, antibody fragment, Fab fragment, or aptamer, can recognize and bind to. For example, in the case of a protein antigen, this may refer to a region of the protein (i.e., amino acids, especially their side chains) to which the antibody binds. A duplicate epitope contains at least 1 to 5 common amino acid residues. Methods for identifying antibody epitopes are known to those skilled in the art, including, for example, those described in Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, Ed Harlow and David Lane (1988).

[0019] The radiolabeled HER3-targeted drugs disclosed herein may be used to treat HER3-positive, i.e., HER3-expressing, cancers or precancerous conditions such as solid tumors. "HER3-positive" or "HER3-expressing" means that at least a portion of cancer cells in a patient, for example, in a tumor, express or overexpress HER3. As used herein, the terms “proliferative disorder” and “cancer” may be used interchangeably and may not limit themselves to include solid tumors (e.g., tumors) and precancerous proliferative disorders. "Solid tumors" that may be treated according to various embodiments of the present invention and that may be HER3-positive include, without limitation, bone cancer, pancreatic cancer, skin cancer, head and neck cancer, melanoma of the skin or eye, uterine cancer, ovarian cancer, prostate cancer, rectal cancer, anal cancer, gastric cancer, testicular cancer, endometrial cancer, fallopian tube cancer, endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer, esophageal cancer, small intestine cancer, endocrine cancer, thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, pediatric tumors, bladder cancer, kidney or ureteral cancer, renal pelvis cancer, central nervous system neoplasms (CNS), primary central nervous system lymphoma, tumor angiogenesis, spinal axial tumors, brainstem gliomas, pituitary adenomas, Kaposi's sarcoma, epidermal carcinoma, squamous cell carcinoma, and environmentally induced cancers such as those caused by asbestos. Such cancers may be metastatic or non-metastatic. Solid tumors that may be treated according to various embodiments of the present invention and that may be HER3-positive may include breast cancers such as tamoxifen-sensitive breast cancer, tamoxifen-resistant breast cancer, HER2-positive breast cancer, HER2-negative breast cancer, or triple-negative breast cancer (TNBC); gastric cancer, bladder cancer, cervical cancer, endometrial cancer, skin cancers such as melanoma; stomach cancer, testicular cancer, esophageal cancer, bronchioloalveolar cancer, prostate cancers such as castration-resistant prostate cancer (CRPC); colorectal cancer, ovarian cancer, cervical epithelioid carcinoma, liver cancers such as hepatocellular carcinoma (HCC) or cholangiocarcinoma; pancreatic cancer, lung cancers such as non-small cell lung cancer (NSCLC); kidney cancer, head and neck cancers such as head and neck squamous cell carcinoma; carcinomas; sarcomas; or any combination thereof. Such cancers may be metastatic or non-metastatic.

[0020] In certain embodiments, HER3-targeted drugs may be labeled with radioisotopes / radionuclides. As used herein, “radioisotopes” and “radionuclides” may be α-radiotopes, β-radiotopes, and / or γ-radiotopes. Exemplary radionuclides that may be used to label targeted drugs such as HER3-targeted drugs include:131 I, 125 I, 123 I, 90 Y, 177 Lu, 186 Re, 188 Re, 89 Sr, 153 Sm, 32 P, 225 Ac, 213 Bi, 213 Po, 211 At, 212 Bi, 213 Bi, 223 Ra, 227 Th, 149 Tb, 137 Cs, 212 Pb, 103 Pd, 134 Ce, 43 Sc, 44 Sc, 47 Sc, 55 ]>Co, 60 Cu, 61 Cu, 62 Cu, 64 Cu, 67 Cu, 66 Ga, 67 Ga, 68 Ga, 82 Rb, 86 Y, 87 Y, 89 Zr, 97 Ru, 105 Rh, 109 Pd, 111 In, 117m Sn, 149 Pm, 149 Tb, 153 Sm, 177 Lu, 199 Au, 201 Tl, and 203Methods for adding radioisotopes to proteins such as antibodies or antibody fragments (i.e., "labeling" proteins with radioisotopes) are well known in the art. Specific compositions and methods for labeling are described, for example, in International Publication No. 2017 / 155937, and in U.S. Provisional Patent Application No. 63 / 042,651 filed on 9 December 2019, and in U.S. Provisional Patent Application No. 63 / 119,093, entitled "Compositions and methods for preparation of site-specific radioconjugates," filed on 30 November 2020, all of which are incorporated herein by reference. Targeted drugs, such as HER3-targeted drugs containing one or more cysteine ​​residues, e.g., peptides, proteins, antibodies, and protein-antibody mimics, may be chemically conjugated to any stable linker containing a chelating agent, such as DOTA, as disclosed in, for example, U.S. Patent No. 11,000,604, entitled “Reagent for site-selective bioconjugation of proteins or antibodies,” relating to radionuclide labeling.

[0021] In a particular manner, HER3-targeted drugs are 225 It is radioactively labeled with Ac (" 225 The "Ac-labeled" antibody may be a peptide or small molecule, and the effective dose may be, for example, 50.0 μCi / kg or less (i.e., administered to the subject). 225 The amount of Ac delivers a radiation dose of less than 50.0 μCi per kg of the subject's body weight. In a specific manner, HER3-targeted drugs 225 When labeled with Ac, the effective dose is 50 μCi / kg, 40 μCi / kg, 30 μCi / kg, 20 μCi / kg, 10 μCi / kg, 5 μCi / kg, 4 μCi / kg, 3 μCi / kg, 2 μCi / kg, 1 μCi / kg, or less than 0.5 μCi / kg. Depending on the specific embodiment, HER3-targeted drugs 225When labeled with Ac, the effective amount is at least 0.05 μCi / kg, or 0.1 μCi / kg, 0.2 μCi / kg, 0.3 μCi / kg, 0.4 μCi / kg, 0.5 μCi / kg, 1 μCi / kg, 2 μCi / kg, 3 μCi / kg, 4 μCi / kg, 5 μCi / kg, 6 μCi / kg, 7 μCi / kg, 8 μCi / kg, 9 μCi / kg, 10 μCi / kg, 12 μCi / kg, 14 μCi / kg, 15 μCi / kg, 16 μCi / kg, 18 μCi / kg, 20 μCi / kg, 30 μCi / kg, or 40 μCi / kg. Depending on the specific embodiment, 225 Ac-labeled antibodies may be administered in doses including any combination of the upper and lower limits described herein, for example, at least 0.1 to 5 μCi / kg or at least 5 to 20 μCi / kg.

[0022] In a particular manner, HER3-targeted drugs are 225 The antibody, peptide, or small molecule may be radiolabeled with Ac, and the effective amount may be 2 mCi or less (i.e., 225 Ac is administered to the subject in a dose not based on body weight. According to a specific embodiment, 225 The effective dose of Ac-labeled HER3-targeted drugs may be less than 1 mCi, for example, 0.9 mCi, 0.8 mCi, 0.7 mCi, 0.6 mCi, 0.5 mCi, 0.4 mCi, 0.3 mCi, 0.2 mCi, 0.1 mCi, 90 μCi, 80 μCi, 70 μCi, 60 μCi, 50 μCi, 40 μCi, 30 μCi, 20 μCi, 10 μCi, or 5 μCi. 225 The effective dose of Ac-labeled HER3-targeted drugs may be at least 2 μCi, for example, at least 5 μCi, 10 μCi, 20 μCi, 30 μCi, 40 μCi, 50 μCi, 60 μCi, 70 μCi, 80 μCi, 90 μCi, 100 μCi, 200 μCi, 300 μCi, 400 μCi, 500 μCi, 600 μCi, 700 μCi, 800 μCi, 900 μCi, 1 mCi, 1.1 mCi, 1.2 mCi, 1.3 mCi, 1.4 mCi, or 1.5 mCi. Depending on the specific embodiment, 225Ac-labeled HER3-targeted drugs may be administered in doses including any combination of the upper and lower limits described herein, for example, at least 2 μCi to 1 mCi or less, or at least 2 to 250 μCi or less, or 75 to 400 μCi or less. In accordance with a particular aspect, 225 Ac-labeled HER3-targeted drugs include single doses delivered primarily to target solid tumors, for example, at doses of less than 12 Gy, or less than 8 Gy, or less than 6 Gy, or less than 4 Gy, or less than 2 Gy, such as 2 to 8 Gy.

[0023] In a particular manner, HER3-targeted drugs are 177 Radioactively labeled with Lu (" 177 The "Lu-labeled" antibody may be a peptide or small molecule, and the effective dose may be, for example, less than 1 mCi / kg (i.e., administered to the subject). 177 The amount of Lu-labeled targeted drug delivers a radiation dose of less than 1000 μCi per kg of the subject's body weight. According to a specific embodiment, the antibody 177 When labeled with Lu, the effective dose is 900 μCi / kg, 800 μCi / kg, 700 μCi / kg, 600 μCi / kg, 500 μCi / kg, 400 μCi / kg, 300 μCi / kg, 200 μCi / kg, 150 μCi / kg, 100 μCi / kg, 80 μCi / kg, 60 μCi / kg, 50 μCi / kg, 40 μCi / kg, 30 μCi / kg, 20 μCi / kg, 10 μCi / kg, 5 μCi / kg, or less than 1 μCi / kg. Depending on the specific embodiment, 177 The effective dose of Lu-labeled antibody is at least 1 μCi / kg, 2.5 μCi / kg, 5 μCi / kg, 10 μCi / kg, 20 μCi / kg, 30 μCi / kg, 40 μCi / kg, 50 μCi / kg, 60 μCi / kg, 70 μCi / kg, 80 μCi / kg, 90 μCi / kg, 100 μCi / kg, 150 μCi / kg, 200 μCi / kg, 250 μCi / kg, 300 μCi / kg, 350 μCi / kg, 400 μCi / kg, or 450 μCi / kg. Depending on the specific embodiment, 177Lu-labeled antibodies may be administered in doses including any combination of the upper and lower limits described herein, for example, at least 5 mCi / kg to 50 μCi / kg or at least 50 mCi / kg to 500 μCi / kg. In a particular manner, HER3-targeted drugs are 177 The antibody may be labeled with Lu, and the effective dose may be less than 45 mCi, for example, 40 mCi, 30 mCi, 20 mCi, 10 mCi, 5 mCi, 3.0 mCi, 2.0 mCi, 1.0 mCi, 800 μCi, 600 μCi, 400 μCi, 200 μCi, 100 μCi, or less than 50 μCi. 177 The effective dose of Lu-labeled HER3-targeted drugs may be at least 10 μCi, for example, at least 25 μCi, 50 μCi, 100 μCi, 200 μCi, 300 μCi, 400 μCi, 500 μCi, 600 μCi, 700 μCi, 800 μCi, 900 μCi, 1 mCi, 2 mCi, 3 mCi, 4 mCi, 5 mCi, 10 mCi, 15 mCi, 20 mCi, 25 mCi, or 30 mCi. Depending on the specific embodiment, 177 Lu-labeled antibodies may be administered in doses including any combination of the upper and lower limits described herein, for example, at least 10 to 30 mCi or less, or at least 100 μCi to 3 mCi or less, or 3 to 30 mCi or less.

[0024] In a particular manner, HER3-targeted drugs are 131 It is radioactively labeled with I (" 131 I-labeled antibodies, peptides, or small molecules may be used, and the effective dose may be, for example, less than 1200 mCi (i.e., administered to the subject). 131 The amount of I delivers a whole-body radiation dose of less than 1200 mCi at a dose not based on body weight. According to a specific embodiment, 131 The effective dose of the I-labeled targeted drug may be less than 1100 mCi, less than 1000 mCi, less than 900 mCi, less than 800 mCi, less than 700 mCi, less than 600 mCi, less than 500 mCi, less than 400 mCi, less than 300 mCi, less than 200 mCi, less than 150 mCi, or less than 100 mCi. Depending on the specific embodiment, 131The effective dose of the I-labeled targeted drug may be less than 200 mCi, for example, less than 190 mCi, 180 mCi, 170 mCi, 160 mCi, 150 mCi, 140 mCi, 130 mCi, 120 mCi, 110 mCi, 100 mCi, 90 mCi, 80 mCi, 70 mCi, 60 mCi, or 50 mCi. Depending on the specific embodiment, 131 The effective dose of the I-labeled target drug may be at least 1 mCi, for example, at least 2 mCi, 3 mCi, 4 mCi, 5 mCi, 6 mCi, 7 mCi, 8 mCi, 9 mCi, 10 mCi, 20 mCi, 30 mCi, 40 mCi, 50 mCi, 60 mCi, 70 mCi, 80 mCi, 90 mCi, 100 mCi, 110 mCi, 120 mCi, 130 mCi, 140 mCi, 150 mCi, 160 mCi, 170 mCi, 180 mCi, 190 mCi, 200 mCi, 250 mCi, 300 mCi, 350 mCi, 400 mCi, 450 mCi, or 500 mCi. Depending on the specific embodiment, 131 I-labeled targeted drugs may be administered in doses including any combination of the upper and lower limits described herein, for example, at least 1 to 100 mCi or less, or at least 10 to 200 mCi or less.

[0025] Selected radionuclides are disclosed in detail herein, but any of those disclosed herein or otherwise may be used to radiolabel targeted drugs such as the radiolabeled HER3 targeted drugs disclosed herein. The compositions containing HER3-targeted drugs used herein include “patient-specific compositions” that include both radionuclide-labeled and unlabeled portions. According to certain embodiments of the present invention, when the HER3-targeted drug is radioisotope-labeled, the majority of the targeted drug (antibody, antibody fragment, etc.) administered to the patient consists of the unlabeled targeted drug, with the radiolabeled targeted drug being only a portion. The ratio of labeled to unlabeled targeted drugs can be adjusted using known methods. According to certain embodiments of the present invention, patient-specific compositions may include HER3-targeted drugs in which the ratio of labeled to unlabeled portions is about 0.01:10 to 1:1, for example, 0.1:10 to 1:1. In accordance with certain aspects of the present invention, HER3-targeted drugs may be provided in amounts of 100 mg or less, for example, 60 mg or less, for example, 5 to 45 mg of total protein or peptide, or in amounts of 0.001 to 3.0 mg / kg patient body weight, for example, 0.005 to 2.0 mg / kg patient body weight, or 0.01 to 1 mg / kg patient body weight, or 0.1 to 0.6 mg / kg patient body weight, or 0.3 mg / kg patient body weight, or 0.4 mg / kg patient body weight, or 0.5 mg / kg patient body weight, or 0.6 mg / kg patient body weight of total protein.

[0026] The combination of radiolabeled and unlabeled portions of targeted drugs, such as antibodies, according to the present invention makes it possible to tailor compositions to specific patients, individualizing the radiation dose of the targeted drug and the protein dose based on at least one of the patient's specific parameters. Thus, each vial of the composition may be prepared for a specific patient, and the entire contents of the vial are delivered to that patient in a single dose. If the treatment regimen indicates multiple doses, each dose may be prescribed as a patient-specific dose in a vial that is administered to the patient as a "single dose" (i.e., the entire contents of the vial are administered at once). Subsequent doses may be prescribed in a similar manner so that each dose of the regimen is filled into a single-dose container as a patient-specific dose. One advantage of such compositions is that there is no residual radiopharmaceutical that would require disposal or handling by healthcare professionals, such as dilution to obtain the dose required by the patient. When provided in single-dose containers, the containers simply need to be placed in a single row on an infusion tubing set for administration to the patient. Furthermore, because the volume can be standardized, the possibility of medical errors (i.e., administering the wrong dose because the entire composition can be administered in a single injection) is significantly reduced. Accordingly, in a particular embodiment, the HER3-targeted drug may be provided as a single-dose composition that can be tailored to a specific patient, and the amounts of radiolabeled and unlabeled HER3-targeted drugs in the composition may vary depending on one or more of the patient's weight, age, sex, medical condition, and / or health status, as described in International Publication No. 2016 / 187514 and U.S. Patent No. 10,736,975. In a particular embodiment, the HER3-targeted drug may be provided as a multi-dose therapeutic, and each dose in the therapeutic regimen may be provided as a patient-specific composition. The patient-specific composition may include radiolabeled and unlabeled HER3-targeted drugs, the amounts of which may vary depending on one or more of the patient's weight, age, sex, medical condition, and / or health status.

[0027] As used herein, the terms “subject” and “patient” are interchangeable and include, without limitation, mammals such as humans, non-human primates, dogs, cats, horses, sheep, goats, cattle, rabbits, pigs, rats, and mice. If the subject is human, the subject's age is irrelevant. For example, the subject may be 60 years or older, 65 years or older, 70 years or older, 75 years or older, 80 years or older, 85 years or older, or 90 years or older. Alternatively, the subject may be 50 years or younger, 45 years or younger, 40 years or younger, 35 years or younger, 30 years or younger, 25 years or younger, or 20 years or younger. In the case of a human subject with cancer, the subject may be newly diagnosed, or relapsed, and / or refractory, or in remission. As used herein, “treating” a subject with cancer means, without limitation, (i) slowing, stopping, or reversing the progression of cancer; (ii) slowing, stopping, or reversing the progression of cancer symptoms; (iii) reducing the likelihood of cancer recurrence; and / or (iv) reducing the likelihood of cancer symptoms recurrence. In a particular preferred manner, treating a subject with cancer means (i) reversing the progression of cancer to the extent that it is ideally eliminated; and / or (ii) reversing the progression of cancer symptoms to the extent that they are ideally eliminated; and / or (iii) reducing or eliminating the likelihood of relapse (i.e., consolidation resulting in the destruction of any remaining cancer cells).

[0028] In the context of this invention, “chemotherapeutic agent” means a compound that inhibits or kills proliferating cells and that can be used or approved for use in the treatment of cancer. Exemplary chemotherapeutic agents include cell proliferation inhibitors that block, interfere with, interrupt, or delay cell division at the level of nuclear division or plasmidal division. Such agents, for example, taxanes, in particular docetaxel or paclitaxel, and epothirones, in particular epothirones A, B, C, D, E, and F, can stabilize microtubules, or vinca alkaloids, in particular vinblastine, vincristine, vindesine, vinflunin, and vinorelbine, etc., can destabilize microtubules. Exemplary chemotherapeutic agents also include radiosensitizers such as temozolomide, cisplatin, and / or fluorouracil, which may exhibit synergistic effects with radiolabeled HER3.

[0029] "Therapeutic dose" or "effective dose" refers to the effective amount in the dosage and duration required to achieve the desired therapeutic outcome. The therapeutic dose may vary depending on factors such as the individual's condition, age, sex, and weight, as well as the ability of the therapeutic agent or combination of therapeutic agents to produce the desired response in the individual. Exemplary indicators of an effective therapeutic agent or combination of therapeutic agents include, for example, improved patient health, reduced tumor burden, cessation or slowing of tumor growth, and / or the absence of metastasis of cancer cells to other parts of the body. Depending on the particular aspect, "therapeutic dose" or "effective dose" refers to the amount of radiolabeled HER3-targeted agent that, when used alone, in combination with other agents and / or therapeutic modes, or together, can deplete or reduce the total number of HER3-expressing cells, and / or inhibit the proliferation of HER3-expressing cells. As used herein with respect to HER3-expressing cells, “deplete” means reducing the population of at least one type of cell that expresses or overexpresses HER3 (e.g., HER3-positive cells circulating in a solid tumor or the blood of the subject). According to certain aspects of the present invention, the reduction is determined by comparing the number of HER3-positive cells in the blood of the subject or in a tissue biopsy, such as a solid tumor, before and after the initiation of treatment with a HER3-targeted drug. Thus, for example, the HER3-positive cells of the subject may be considered depleted if the cell population is reduced by, for example, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 99%. "Inhibits growth" means a measurable reduction or delay in the growth of malignant cells or tissues (e.g., tumors) in vitro or in vivo, compared to the reduction or delay in the growth of the same cells or tissues in the absence of the drug or combination of drugs, when exposed to the drug or combination of drugs. The inhibition of growth of malignant cells or tissues in vitro or in vivo may be at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, or 100%.

[0030] The term "immune checkpoint therapy" refers to molecules that can modulate the function of immune checkpoint proteins in a positive or negative direction in promoting the immune response against cancer cells. The term "immune checkpoint" refers to proteins that, under normal physiological conditions, are directly or indirectly involved in immune pathways that block uncontrolled immune responses, thereby maintaining autoimmune tolerance and / or tissue defense. In the context of the present invention, immune checkpoint therapeutics include therapeutic agents such as antibodies that can at least partially downregulate the function of suppressive immune checkpoints (antagonists) and / or at least partially upregulate the function of stimulating immune checkpoints (agonists). For example, immune checkpoint therapeutics may refer to antibodies against immune checkpoint inhibitors (ICIs) that may be upregulated in certain cancers and therefore may inhibit the function of ICIs.

[0031] The term "DDRi" refers to an inhibitor of DNA damage response pathway proteins, one example being PARPi. The term "PARPi" also refers to an inhibitor of poly(ADP-ribose) polymerase. In the context of this invention, the term PARPi encompasses molecules, such as antibodies, peptides, or small molecules, that bind to poly(ADP-ribose) polymerase and inhibit its function. The term "CD47 blocker" refers to drugs that prevent CD47 from binding to SIRPα, such as blockers that bind to either CD47 or SIRPα, blockers that modulate the expression of CD47 or SIRPα, or blockers that otherwise inhibit the CD47 / SIRPα axis. CD47 blockers include, but are not limited to, at least antibodies that bind to CD47, such as maglorimab, remzopalimab, and AO-176; SIRPα fusion proteins, such as TTI-621 and TTI-622; drugs that modulate the expression of CD47 and / or SIRPα, such as phosphorodiamidate morpholino oligomers (PMOs) that inhibit the translation of CD47; and small molecule drugs, such as RRx-001.

[0032] As used herein, administering one or more additional therapeutic agents "together" with a HER3-targeted drug, such as immune checkpoint therapy and / or DDRi and / or CD47 blockers and / or radiosensitizers, means administering the additional therapeutic agent before, during, and / or after administration of the HER3-targeted drug. This administration includes, but is not limited to, the following scenarios: (i) administering the additional therapeutic agent first and the HER3-targeted drug second; (ii) administering the additional therapeutic agent concurrently with the HER3-targeted drug (e.g., orally administering DDRi once daily for n days and administering a single intravenous dose of the HER3-targeted drug on any day from day 2 to day n-1 of the DDRi regimen); (iii) administering the additional therapeutic agent concurrently with the HER3-targeted drug (e.g., orally administering DDRi for a period of more than one month, e.g., 35 days, 42 days, 49 days, or if the cancer progresses during treatment) (iv) administering the HER3-targeted drug orally once daily for a period longer than that during which DDRi does not cause unacceptable toxicity, and administering a single intravenous dose of the HER3-targeted drug once daily during the first month of the DDRi regimen; and (iv) administering the HER3-targeted drug first (e.g., a single intravenous dose or multiple doses over several weeks), followed by the administration of the additional therapeutic agent (e.g., administering DDRi orally once daily for 21, 28, 35, 42, 49 days, or longer than that during which the cancer does not progress and DDRi does not cause unacceptable toxicity). Other permutations that would be obvious to those skilled in the art are also possible and fall within the scope of the inventions claimed herein.

[0033] "Product" refers to packaging containing a substance useful for the treatment, prevention, and / or diagnosis of the disorders described herein. A product may include a container and labels or accompanying documents on or associated with the container. Suitable containers include, for example, bottles, vials, syringes, and IV solution bags. Containers may be formed from a variety of materials, such as glass or plastic. A container may hold a composition effective for the treatment, prevention, and / or diagnosis of a condition, either by itself or in combination with another composition, and may have a sterile access port (for example, a container may be an intravenous solution bag or vial with a stopper that can be punctured with a subcutaneous needle). At least one activator in the composition may be a radiolabeled HER3-targeted drug according to the embodiments of the present invention disclosed herein. The terms “label” or “package insert” are typically used to refer to instructions contained in the commercial packaging of a therapeutic product, which contain information regarding indications, usage, dosage, administration, combination therapy, contraindications, and / or warnings relating to the use of such therapeutic product. As used herein, labels may indicate that the composition is used to treat HER3-positive cancer and may optionally indicate the route and / or method of administration. Furthermore, the product may include (a) a first container containing a composition in which the composition is a HER3-targeting agent; and (b) a second container containing a composition in which the composition is a further cytotoxic agent or other therapeutic agent according to the present invention disclosed herein. Alternatively or additionally, the product may further include a second (or third) container containing a pharmaceutically acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution, and dextrose solution. This may further include other materials desirable from a commercial and user perspective, including other buffers, diluents, filters, needles, and syringes.

[0034] Throughout this application, various patents, patent applications, and other publications are referenced, each incorporated herein by reference in whole. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by a person of ordinary skill in the art to which the present invention pertains. Similar or equivalent methods and materials may be used in the practices or tests described herein, but preferred methods and materials are described below.

[0035] Experimental results Anti-HER3 IgG monoclonal antibodies consisting of heavy chain SEQ ID NO: 77 and light chain SEQ ID NO: 78 were prepared, conjugated with the chelating agent DOTA using p-SCN-Bn-DOTA, and radiolabeled by chelation with actinium-225 for further investigation as described below in relation to Figures 3-11. Figure 3 shows the results of comparing Ac with unmodified anti-HER3 antibodies and nonspecific antibodies (IgG), demonstrating that modification does not substantially affect immunoreactivity to HER3. 225 This graph shows the binding characteristics of labeled DOTA-conjugated anti-HER3 monoclonal antibody ("HER3-ARC") as determined by an ELISA assay. 225 The binding properties of Ac-HER3-ARC were evaluated by ELISA. After coating a 96-well plate with human recombinant HER3 overnight, anti-HER3 was used. 225 Serial dilutions (0-100 μg / mL) of Ac-HER3-ARC and IgG (immunoglobulin 1, non-specific IgG1 control) were incubated at room temperature for 1 hour. Secondary antibody (goat anti-human IgG F(ab')20-HRP) was added, incubated on ice for 30 minutes, and then colored with 1M HCl for 10 minutes. Sample absorbance was measured at 450 nm. In ELISA, 225 Ac-HER3-ARC showed binding properties similar to those of native antibodies (HER3-ARC:EC 50 = 0.0017 μg / mL, HER3:EC 50 (=0.0022 μg / mL).

[0036] Figure 4 shows the reaction between HER3-positive NCI-H1975 cells (human lung adenocarcinoma, NSCLC) and BxPC-3 cells (human pancreatic adenocarcinoma).225 This graph shows the results of a flow cytometry assay examining the binding of Ac-HER3-ARC, an unmodified anti-HER3 mAb, a nonspecific antibody control (IgG), and a control consisting only of a secondary antibody. 225 The binding properties of Ac-HER3-ARC were evaluated by flow cytometry in HER3+ cells (NCI-H1975 and BxPC3). Anti-HER3, 225 A solution of Ac-HER3-ARC and IgG (immunoglobulin 1, nonspecific IgG1) (100 μg / mL) was added to HER+ cells and incubated at room temperature for 1 hour. PE-labeled secondary antibody was added and incubated on ice for 30 minutes. Sample fluorescence was measured using a flow cytometer. 225 The binding properties of Ac-HER3-ARC to HER3+ positive cell lines were similar to those of unmodified anti-HER3 mAbs.

[0037] Figure 5 shows the results for the HER3-positive cell line NCI-H1975. 225 This graph shows the in vitro cytotoxic effect of Ac-HER3-ARC as a function of radiation dose. against HER3+ cell line NCI-H19755 225 The cytotoxic effect of Ac-HER3-ARC was evaluated by a colorimetric assay using CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay (MTS). NCI-H1975 cells were used. 225 The samples were incubated with Ac-HER3-ARC at 37°C for 24 hours. Then, the unbound samples were removed. 225 Ac-HER3-ARC was removed, and the cells were cultured at 37°C for 72 hours. The absorbance at 490 nm was measured, and the cell viability (%) was calculated. 225 Ac-HER3-ARC showed potent in vitro cytotoxicity against the HER3+ cell line NCI-H1975.

[0038] Figure 6A shows, 225Figure 6B shows a graph demonstrating that Ac-HER3-ARC upregulates cell surface calreticulin (CRT) in NCI-H1975 cells. 225 This graph shows that Ac-HER3-ARC upregulates CD47 on NCI-H1975 cells. Cell surface expression of calreticulin (CRT) and CD47 by HER3+ cell line NCI-H1975 225 The effects of Ac-HER3-ARC were investigated using flow cytometry. 225 Cells were treated with Ac-HER3-ARC (100 nCi / mL) or PBS (control) for 72 hours. After treatment, cells were stained for CRT and CD47. The results showed that CRT (Figure 6A) and CD47 (Figure 6B) were present in NCI-H1975 cells, respectively. 225 It was shown that it is upregulated by Ac-HER3-ARC.

[0039] Figure 7A shows, 225 This graph shows the results of a phagocytic assay demonstrating that the combination of Ac-HER3-ARC and an anti-CD47 blocking antibody enhanced the phagocytic activity of BxPC-3 cells compared to either treatment alone. Figure 7B shows the results of this assay. 225 This graph shows the results of a phagocytosis assay demonstrating that the combination of Ac-HER3-ARC and an anti-CD47 blocking antibody enhanced the phagocytic activity of NCI-H1975 cells compared to either treatment alone. The same legend was used in Figures 7A and 7B. 225 The effect of the combined use of Ac-HER3-ARC and anti-CD47 on phagocytosis in vitro was evaluated by flow cytometry. BxPC-3 (Figure 7A) and NCI-H1975 (Figure 7B) cells were seeded in 6-well plates, and after 24 hours, 225 The cells were incubated with Ac-HER3-ARC at 37°C for 24 hours. 225 After treatment with Ac-HER3-ARC, the cells were cultured at 37°C for 72 hours. BxPC-3 and NCI-H1975 cells were stained with Vybrant DiD cell-labeled solution and treated with anti-human CD47 (Bio X Cell, catalog number: BE0019) and mouse IgG1 isotype control (Bio X Cell, catalog number: BE0083) at 37°C for 1 hour. Human macrophages were stained with DiO cell-labeled solution. Labeled human macrophages and target cells were co-cultured at 37°C for 2 hours. Phagocytosis was evaluated by examining double-labeled cells (DiD+ / DiO+).

[0040] Figure 8 shows the effects of various radiation doses (100 nCi, 200 nCi, 400 nCi, 600 nCi) in a mouse xenograft model of human tumor (NCI-H1975 cells) compared to 200 nCi alone and in combination with an anti-CD47 blocking antibody. 225 This graph shows the effects of Ac-HER3-ARC, unlabeled anti-HER3 mAb, anti-CD47 blocking antibody alone, and vehicle-only control on tumor growth. In particular, tumor growth is shown at radiation doses of 200 nCi, 400 nCi, and 600 nCi. 225 By AcHER3-ARC, and 225 The combined use of Ac-HER3-ARC(200nCi) and an anti-CD47 mAb resulted in almost complete suppression. Figure 9 is a graph showing the weight over time of the subjects in the experiment described in Figure 8. Figure 10 is a graph showing the survival rate over time in the experimental group of the experiment described in Figure 8. Tumor xenograft studies were also conducted to investigate the effects of HER2-ARC treatment alone and in combination with CD47 blockers on HER2-positive tumor growth. The anti-HER2 mAb trastuzumab was chemically conjugated to DOTA using p-SCN-Bn-DOTA and then chelated with either actinium-225 or lutetium-177 for use in these experiments.

[0041] Figure 11 shows the results of a xenograft model of NGS mice using the HER2-positive SK-OV3 human ovarian cancer cell line, comparing vehicle alone (control) and maglolimab monotherapy (10 mg / kg). 225Acetol trastuzumab alone (0.025 μCi / animal) and maglorimab (10 mg / kg) 225 This graph compares the effects of concomitant use of Ac trastuzumab (0.025 μCi / animal) on tumor growth. Figure 12 shows the results of a xenograft model of NGS mice using the HER2-positive SK-OV3 human ovarian cancer cell line, comparing vehicle alone (control) and maglolimab monotherapy (10 mg / kg). 177 Lutrastuzumab alone (25 μCi / animal) and maglorimab (10 mg / kg) 177 This graph compares the effects of combination therapy with lutrastuzumab (25 μCi / animal) on tumor growth. Each cohort consisted of 8 animals.

[0042] Embodiments of the Invention The possibility of HER3 levels being downregulated after administration of HER3-targeted antibodies has been well supported in both preclinical and clinical trials (Mishra, 2018). In a preclinical model using lumuretuzumab, dose-dependent (1–10 mg / kg) downregulation of HER3 was measured by both immunohistochemistry and Western blotting (Maneses-Lorenta, 2015; Mirshberger, 2013). The lowest dose of lumuretuzumab (0.3 mg / kg) did not result in HER3 target downregulation (Maneses-Lorenta, 2015), and these low doses of lumuretuzumab (0.1 mg / kg and 0.3 mg / kg) were ineffective in controlling HER3-expressing tumors (Mirshberger, 2013). In clinical trials using lumuretuzumab, surface HER3 downregulation was observed in 92% of patients in serial tumor biopsies at all tested dose levels (100–2000 mg) (Meulendijks, 2016). Furthermore, in patients treated with 40 mg / kg of the HER3-targeted antibody LJM716, a decrease in total HER3 levels was observed in 3 out of 5 tumor biopsy samples (Reynolds, 2017). Internalization and degradation of HER3 may be beneficial in suppressing HER3 phosphorylation and subsequent signaling activity, but a decrease in HER3 surface levels may hinder antibody targeting of tumors. Therefore, when repeated administration of HER3-targeted antibodies is desired or required for efficacy, administration of the HER3-targeted antibody may result in target downregulation, potentially eliminating the need for re-administration. The inventors have found that the use of antibody-radioactive material conjugates (ARCs) avoids the problems associated with dose-dependent downregulation of HER3, as low antibody doses useful for therapeutic methods may not cause HER3 downregulation. Accordingly, the inventors have found that HER3-targeted drugs containing radioisotopes are effective as diagnostic and therapeutic agents that improve tumor targeting and killing of HER3-expressing cancer cells, such as certain solid tumors. In particular, therapeutic methods that may involve multiple administrations of HER3-targeted drugs may result in improved tumor targeting and killing without causing harmful levels of HER3 downregulation.

[0043] Accordingly, a method for treating HER3-positive cancer using a radiolabeled HER3-targeted drug is provided according to certain aspects of the present invention disclosed herein. The method may also include a diagnostic step of determining whether and / or to what extent a patient has HER3-positive cancer and / or localization of such cancer by, for example, identifying and / or quantifying HER3-positive cells in a solid tumor or circulating in a sample of the patient's blood. In a particular embodiment, the treatment method includes administering a radiolabeled HER3-targeted agent, such as a radiolabeled antibody, peptide, or small molecule that targets HER3, either alone or in combination with one or more additional agents or modes of treatment. In a particular embodiment, the additional agents or modes may be any one or more of the following: immune checkpoint agents, DDRi, CD47 blockers, chemotherapeutic agents, small molecule antitumor agents, external beam radiation therapy, and brachytherapy.

[0044] In a particular manner, radiolabeled HER3-targeted drugs may be administered to patients in single or multiple doses as patient-specific compositions. In accordance with specific embodiments, patients may be monitored for the presence of HER3-positive cells at intervals during treatment to assess the reduction in HER3-positive cells. Detecting a decrease in the number of HER3-positive cells after treatment compared to the number of HER3-positive cells before treatment with a HER3-targeted drug may demonstrate the effectiveness of HER3-targeted drugs in the treatment of HER3-positive cancers in mammals. In a particular embodiment, a method of treating cancer includes identifying patients with HER3-positive cancer by identifying HER3-positive cells, and administering an effective dose of a HER3-targeted drug to the patient, either alone or in combination with an additional treatment. In a particular embodiment, the additional treatment may be any one or more of the following: immune checkpoint drugs, DDRi, CD47 blockers, chemotherapy drugs, small molecule antitumor drugs, external beam radiation therapy, and brachytherapy. In certain contexts, chemotherapy drugs are radiosensitizers. In certain embodiments, radiolabeled HER3-targeted drugs can be administered to patients who are undergoing or have recently undergone cancer treatment, such as surgery to remove all or part of a solid tumor. Therefore, for example, radiolabeled HER3-targeted drugs can be administered perioperatively or postoperatively.

[0045] HER3-targeted drugs An object of the present invention disclosed herein is to provide radiolabeled HER3-targeted drugs, such as human HER3-targeted drugs, for diagnostic and / or therapeutic purposes, such as in the diagnosis and / or treatment of HER3-positive cancer. Radiolabeled HER3-targeted drugs can induce a therapeutic response by delivering ionizing radiation that damages DNA, such as alpha particles that induce double-strand DNA breaks and cell death, to cells. Exemplary anti-HER3 antibodies (also referred to herein as "HER3 antibodies"), such as radiolabeled anti-human HER3 antibodies that can be embodied and / or used in various embodiments of the present invention disclosed herein, include, but are not limited to, antibodies and immunoglobulins, such as, (i) an antibody comprising the heavy chain variable region or heavy chain; (ii) an antibody comprising one, two, or three of the HER3 antibody heavy chain CDR (e.g., as defined by Kabat) or heavy chain or referred to thereof; (iii) an antibody comprising the light chain variable region or light chain; and / or (iv) an antibody comprising one, two, or three of the HER3 antibody light chain CDR (e.g., as defined by Kabat) or light chain or referred to thereof. Furthermore, where a HER3 antibody heavy chain or HER3 antibody light chain comprising an N-terminal leader sequence is disclosed, it should be understood that corresponding heavy chains and corresponding light chains lacking the leader sequence are also intended to be disclosed for embodiment and use in various embodiments of the present invention.

[0046] Exemplary HER3 antibodies that are radiolabeled and may be embodied and / or used in the invention disclosed herein may include, for example, a mouse monoclonal antibody against HER3 comprising a heavy chain having the amino acid sequence specified in SEQ ID NO: 9 or 11, and / or a light chain having the amino acid sequence specified in SEQ ID NO: 10 or 12, or an antibody such as a humanized antibody derived from one or more of the aforementioned sequences. Exemplary HER3 antibodies that are radiolabeled and may be embodied and / or used in the invention disclosed herein may include a heavy chain having an N-terminal region having the sequence specified in SEQ ID NO: 13, and / or a light chain having an N-terminal region having the sequence specified in SEQ ID NO: 14. HER3 antibodies that can be similarly embodied or used in various embodiments of the present invention may include, for example, a heavy chain variable region having the amino acid sequence specified in SEQ ID NO: 7, and / or a light chain variable region having the amino acid sequence specified in SEQ ID NO: 8; and / or a heavy chain containing one or more of CDR1, CDR2, and CDR3 having the amino acid sequences specified in SEQ ID NOs: 1 to 3, respectively, and / or a light chain containing one or more of CDR1, CDR2, and CDR3 having the amino acid sequences specified in SEQ ID NOs: 4 to 6, respectively. For further descriptions of these sequences, see Figures 1 and 2. HER3 antibodies that can be embodied and / or used in any aspect of the present invention may include, for example, any combination of the aforementioned light chain sequences and / or heavy chain sequences.

[0047] An exemplary HER3 antibody includes an immunoglobulin heavy chain variable region including CDR-H1 containing SEQ ID NO: 15, CDR-H2 containing SEQ ID NO: 16, and CDR-H3 containing SEQ ID NO: 17, and / or an immunoglobulin light chain variable region including CDR-L1 containing SEQ ID NO: 18, CDR-L2 containing SEQ ID NO: 19, and CDR-L3 containing SEQ ID NO: 20. An exemplary HER3 antibody includes an immunoglobulin heavy chain variable region including SEQ ID NO: 21 and / or an immunoglobulin light chain variable region including SEQ ID NO: 22. An exemplary HER3 antibody includes the immunoglobulin heavy chain amino acid sequence of SEQ ID NO: 23 and / or the immunoglobulin light chain amino acid sequence of SEQ ID NO: 24. An exemplary HER3 antibody includes an immunoglobulin heavy chain variable region containing CDR-H1 containing SEQ ID NO: 25, CDR-H2 containing SEQ ID NO: 26, and CDR-H3 containing SEQ ID NO: 27; and / or an immunoglobulin light chain variable region containing CDR-L1 containing SEQ ID NO: 28, CDR-L2 containing SEQ ID NO: 29, and CDR-L3 containing SEQ ID NO: 30. An exemplary HER3 antibody includes an immunoglobulin heavy chain variable region containing SEQ ID NO: 31 and / or an immunoglobulin light chain variable region containing SEQ ID NO: 32. An exemplary HER3 antibody includes the immunoglobulin heavy chain amino acid sequence of SEQ ID NO: 33 and / or the immunoglobulin light chain amino acid sequence of SEQ ID NO: 34.

[0048] An exemplary HER3 antibody includes an immunoglobulin heavy chain variable region containing CDR-H1 containing SEQ ID NO: 35, CDR-H2 containing SEQ ID NO: 36, and CDR-H3 containing SEQ ID NO: 37; and / or an immunoglobulin light chain variable region containing CDR-L1 containing SEQ ID NO: 38, CDR-L2 containing SEQ ID NO: 39, and CDR-L3 containing SEQ ID NO: 40. An exemplary HER3 antibody includes an immunoglobulin heavy chain variable region containing SEQ ID NO: 41 and / or an immunoglobulin light chain variable region containing SEQ ID NO: 42. An exemplary HER3 antibody includes the immunoglobulin heavy chain amino acid sequence of SEQ ID NO: 43 and the immunoglobulin light chain amino acid sequence of SEQ ID NO: 44. An exemplary HER3 antibody includes an immunoglobulin heavy chain variable region containing CDR-H1 containing SEQ ID NO: 45, CDR-H2 containing SEQ ID NO: 46, and CDR-H3 containing SEQ ID NO: 47; and / or an immunoglobulin light chain variable region containing CDR-L1 containing SEQ ID NO: 48, CDR-L2 containing SEQ ID NO: 29, and CDR-L3 containing SEQ ID NO: 49. An exemplary HER3 antibody includes an immunoglobulin heavy chain variable region containing SEQ ID NO: 50 and / or an immunoglobulin light chain variable region containing SEQ ID NO: 51. An exemplary HER3 antibody includes the immunoglobulin heavy chain amino acid sequence of SEQ ID NO: 52 and / or the immunoglobulin light chain amino acid sequence of SEQ ID NO: 53.

[0049] An exemplary HER3 antibody includes an immunoglobulin heavy chain variable region containing CDR-H1 containing SEQ ID NO: 54, CDR-H2 containing SEQ ID NO: 55, and CDR-H3 containing SEQ ID NO: 56; and / or an immunoglobulin light chain variable region containing CDR-L1 containing SEQ ID NO: 28, CDR-L2 containing SEQ ID NO: 29, and CDR-L3 containing SEQ ID NO: 30. An exemplary HER3 antibody includes an immunoglobulin heavy chain variable region containing SEQ ID NO: 57 and / or an immunoglobulin light chain variable region containing SEQ ID NO: 58. An exemplary HER3 antibody includes the immunoglobulin heavy chain amino acid sequence of SEQ ID NO: 59 and / or the immunoglobulin light chain amino acid sequence of SEQ ID NO: 60. An exemplary HER3 antibody includes an immunoglobulin heavy chain variable region containing CDR-H1 containing SEQ ID NO: 61, CDR-H2 containing SEQ ID NO: 62, and CDR-H3 containing SEQ ID NO: 63; and / or an immunoglobulin light chain variable region containing CDR-L1 containing SEQ ID NO: 64, CDR-L2 containing SEQ ID NO: 65, and CDR-L3 containing SEQ ID NO: 66. An exemplary HER3 antibody includes an immunoglobulin heavy chain variable region containing SEQ ID NO: 67 and / or an immunoglobulin light chain variable region containing SEQ ID NO: 68. An exemplary HER3 antibody includes the immunoglobulin heavy chain amino acid sequence of SEQ ID NO: 69 and the immunoglobulin light chain amino acid sequence of SEQ ID NO: 70.

[0050] An exemplary HER3 antibody includes an immunoglobulin heavy chain variable region containing CDR-H1 containing SEQ ID NO: 71, CDR-H2 containing SEQ ID NO: 72, and CDR-H3 containing SEQ ID NO: 66; and / or an immunoglobulin light chain variable region containing CDR-L1 containing SEQ ID NO: 28, CDR-L2 containing SEQ ID NO: 29, and CDR-L3 containing SEQ ID NO: 30. An exemplary HER3 antibody includes an immunoglobulin heavy chain variable region containing SEQ ID NO: 73 and / or an immunoglobulin light chain variable region containing SEQ ID NO: 74. An exemplary HER3 antibody includes the immunoglobulin heavy chain amino acid sequence of SEQ ID NO: 75 and / or the immunoglobulin light chain amino acid sequence of SEQ ID NO: 76. An exemplary HER3 antibody contains the immunoglobulin heavy chain amino acid sequence of SEQ ID NO: 77 and / or the immunoglobulin light chain amino acid sequence of SEQ ID NO: 78. Exemplary HER3 antibodies include an immunoglobulin light chain variable region containing SEQ ID NOs: 86, 87, 88, 89, 90, or 91, and / or a heavy chain variable region containing SEQ ID NOs: 79, 80, 81, 82, 83, 84, or 85. An example HER3 antibody comprises an immunoglobulin heavy chain sequence including SEQ ID NOs: 92, 94, 95, 98, or 99, and / or an immunoglobulin light chain sequence including SEQ ID NOs: 93, 96, 97, 100, or 101.

[0051] Exemplary HER3 antibodies include baracetamab (ISU104) from Isu Abxis Co. and any of the HER3 antibodies disclosed in U.S. Patent No. 10,413,607. Exemplary HER3 antibodies include HMBD-001(10D1F) from Hummingbird Bioscience Pte., as well as any of the HER3 antibodies disclosed in International Publication Nos. 2019185164 and 2019185878, U.S. Patent No. 10,662,241; and U.S. Patent Application Publication Nos. 20190300624, 20210024651, and 20200308275. Exemplary HER3 antibodies include Merus NV's HER2 / HER3 bispecific antibody MCLA-128 (i.e., xenoctuzumab), as well as any HER3 antibodies, monospecific or polyspecific, disclosed in U.S. Patent Publication Nos. 20210206875, 20210155698, 20200102393, 20170058035, and 20170037145. Exemplary HER3 antibodies include the HER3 antibody patritumab (U3-1287), an antibody containing the reported chain of patritumab, heavy chain sequence SEQ ID NO: 106 and / or light chain sequence SEQ ID NO: 7, and any of the HER3 antibodies disclosed in U.S. Patent Nos. 9,249,230 and 7,705,130, and International Publication No. 2007077028. Exemplary HER3 antibodies include HER3 antibody MM-121, and any of the HER3 antibodies disclosed in U.S. Patent No. 7,846,440 and International Publication No. 2008100624. Exemplary HER3 antibodies also include EGFR / HER3 bispecific antibody DL1, and any of the HER3 antibodies, monospecific or polyspecific, disclosed in U.S. Patent Nos. 9,327,035 and 8,597,652, U.S. Patent Application Publication No. 20140193414, and International Publication No. 2010108127. Exemplary HER3 antibodies include HER2 / HER3 bispecific antibody MM-111, as well as any HER3 antibodies, monospecific or polyspecific, disclosed in U.S. Patent Nos. 20130183311 and 20090246206, and International Publication Nos. 2006091209 and 2005117973.

[0052] In a particular embodiment, HER3-targeted drugs include anti-HER3 antibodies that bind to HER3 epitopes recognized by Daiichi Sankyo's patritumab, Merrimack Pharmaceuticals' cerivanthumab (MM-121), Roche's lumuretuzumab, Novartis' elgemtumab, GlaxoSmithKline's GSK2849330, Celldex Therapeutics' CDX-3379, MediPharma's EV20 and MP-RM-1, Isu Abxis Co.'s valasetamab (ISU104), Hummingbird Bioscience Pte.'s HMBD-001 (10D1F), Regeneron Pharmaceuticals' REGN1400, and / or AVEO Oncology's AV-203. Depending on the specific embodiment, the anti-HER3 antibody may be selected from one or more of the following: patritumab, cerivanthumab, or an antibody containing heavy chain sequence number 108 and / or light chain sequence number 109 reported for cerivanthumab; lumuletuzumab, or an antibody containing heavy chain sequence number 110 and / or light chain sequence number 111 reported for lumuletuzumab; elgemzumab, or an antibody containing heavy chain sequence number 112 and / or light chain sequence number 113 reported for elgemzumab; AV-203, CDX-3379, GSK2849330, EV20, MP-RM-1, ISU104, HMBD-001(10D1F), and REGN1400. Exemplary antibodies in conjunction with exemplary therapeutic indications are also listed in Table 1. [Table 1]

[0053] Wherever specific antibodies, specific antibody heavy chains, and specific antibody light chains against HER3 or any target are disclosed in this disclosure, it should also be understood that for embodiment or use in various aspects of the present invention, it is also intended to be disclosed (i) including the heavy chain variable region or heavy chain of the disclosed antibody, (ii) including one, two, or three of the heavy chain CDRs (e.g., as defined by Kabat) or heavy chains of the disclosed antibody, (iii) including the light chain variable region or light chain of the disclosed antibody, and / or (iv) including one, two, or three of the light chain CDRs (e.g., as defined by Kabat) or light chains of the disclosed antibody, such as immunoglobulins, but not limited to IgG. Furthermore, wherever an antibody heavy chain or antibody light chain including an N-terminal leader sequence is disclosed in this disclosure, it should also be understood that for embodiment and use in various aspects of the present invention, corresponding heavy chains and corresponding light chains lacking a leader sequence are also intended to be disclosed. Furthermore, the present invention provides modified versions of any of the mentioned amino acid sequences in which one or more isomeric amino acid substitutions having exactly the same mass, such as Leu to Ile or vice versa (for example, in any of sequence numbers 1 to 14 shown in Figures 1 and 2). Moreover, specific portions of these sequences can be substituted with relevant portions of human immunoglobulins, etc., to form chimeric immunoglobulins (i.e., chimeric or humanized HER3). Exemplary substitutions include all or part of human leader sequences, and / or conserved regions of human IgG1, IgG2, or IgG4 heavy chains and / or human κ light chains.

[0054] The sequences and structures of human HER3, human HER2, and human EGFR (HER1) are all known. The amino acid sequence of the human HER3 precursor protein (receptor tyrosine protein kinase erbB-3 isoform 1 precursor NCBI reference sequence: NP_001973.2) is provided herein as Sequence ID: 115. Those skilled in the art will readily understand that specific known target protein amino acid sequences, various suitable antibodies, and antibody mimics, which are specific to the extracellular domain of HER3 such as human HER3, can be prepared using immunization and / or planning and / or antibody engineering techniques well established in the art for use in various embodiments of the present invention. HER3-targeted drugs to be radiolabeled for use in various embodiments of the present invention may include, for example, HER3-binding peptides containing a chelating agent, HER3-binding peptides containing DOTA, or any of those disclosed in U.S. Patent Application Publication No. 20200121814.

[0055] In a particular embodiment, HER3-targeted drugs are or include multispecific targeted drugs such as multispecific antibodies against a primary epitope of HER3 and at least a secondary epitope of HER3, or against HER3 and one or more different antigens, e.g., EGFR (HER1), HER2, TROP2, and one or more T-cell receptor γ (TCRγ) chain substitute leading frame proteins (TRAPs). Examples of multispecific antibodies that may be used include HER3 / HER2-targeted antibodies such as MM-111 from Merrimack Pharmaceuticals or MCLA-128 from Merus NV (i.e., xenoctuzumab); or IGF-1R / HER3-targeted antibodies such as MM-141 from Merrimack Pharmaceuticals (i.e., istilatumab); or EGFR / HER3-targeted antibodies such as MEHD7945A from Roche (i.e., durigotumab); or cetuximab-based bispecific or multispecific Zybody from Zyngenia Inc. In a particular aspect, a composition is provided and / or used comprising a mixture of a HER3-targeting drug, such as an antibody against HER3, and one or more antibodies against one or more different antigens, wherein one or more of the antibodies are radiolabeled. An exemplary antibody composition comprising the antibody mixture comprises Symphogen's Sym013, which has at least six monoclonal antibodies against EGFR(HER1), HER2, and HER3. In one aspect of the present invention, one or more antibodies of Sym013, such as anti-HER3 antibodies, may be radiolabeled. Related aspects of the present invention provide a composition comprising a targeted drug, such as an antibody against EGFR(HER1), HER2, and HER3, in which one or more or all of any combination are radiolabeled.

[0056] The present invention further provides multispecific targeted drugs, compositions, and related methods for treating proliferative disorders, including: (i) administration of a multispecific antibody against two or more epitopes of HER3, or against an epitope of HER3 and one or more additional different antigenic epitopes; and / or (ii) administration of a HER3-targeted drug, such as an antibody, and one or more separate targeted drugs against one or more cancer-associated antigens, wherein one or more of the targeted drugs, such as the HER3-targeted drug, are radiolabeled. The additional different antigens may be, for example, antigens whose expression is upregulated on cells involved in various diseases or disorders, such as proliferative disorders, such as solid tumors, such as antigens in which HER3 is also upregulated or potentially upregulated. For example, various additional antigens include mesothelin, TSHR, CD19, CD123, CD22, CD30, CD45, CD171, CD138, CS-1, CLL-1, GD2, GD3, B-cell maturation antigen (BCMA), and TnAg, prostate-specific membrane antigen (PSMA), ROR1, FLT3, TROP2, T cell receptor γ (TCRγ) chain substitute reading frame protein (TRAP), fibroblast activating protein (FAP), calreticulin, phosphatidylserine, GRP78 (BiP), TAG72, CD38, CD44v6, CEA, EPCAM, B7H3, KIT, IL-13Ra2, interleukin-11 receptor a (IL-11Ra), PSCA, PRSS21, VEGFR2, Lewis Y, CD24, platelet-derived growth factor receptor β (PDGFR-β), SSEA-4, CD20, folate receptor α (FRα), ERBB2 (Her2 / neu), MUCl, epidermal growth factor receptor (EGFR) EGFRvIII, NCAM, prostase, PAP, ELF2M, ephrin B2, IGF-I receptor, CAIX, LMP2, gplOO, bcr-abl, tyrosinase, EphA2, fucosyl GM1, sLe, GM3, DR5, 5T4, TGS5, HMWMAA, o-acetyl-GD2, folate receptor β, TEM1 / CD248, TEM7R, CLDN6, GPRC5D, CXORF61, CD97, CD179a, ALK, polysialic acid, PLAC1, GloboH, NY-BR-1, UPK2, HAVCR1, ADRB3, PANX3, GPR20, LY6K, OR51E2, TARP, WT1, NY-ESO-1, LAGE-la, MAGE-A1, regmine, HPV E6 / E7, MAGE Al, MAGEA3, MAGEA3 / A6, ETV6-AML, sperm protein 17, XAGE1, Tie2, MAD-CT-1, MAD-CT-2, Fos-related antigen 1, prostain, survivor and telomerase, PCTA-I / galectin 8, KRAS, MelanA / MARTI, Ras variant, hTERT, sarcoma translocation breakpoint, ML-IAP, ERG (TMPRSS2 ETS fusion gene), NA17, PAX3, androgen receptor, cyclin B1, MYCN, RhoC, TRP-2, CYP1B1, BORIS, SART3, PAX5, OY-TES1, LCK, AKAP-4, SSX2, RAGE-1, human telomerase reverse transcriptase, RU1, RU2, intestinal carboxylesterase, mutThe group may be selected from hsp70-2, CD79a, CD79b, CD72, LAIR1, FCAR, LILRA2, CD300LF, CLEC12A, BST2, EMR2, LY75, GPC3, FCRL5, GPA7, and IGLL1.

[0057] Exemplary DR5 (cell death receptor 5) targeted agents that may be radiolabeled, unlabeled, or drug conjugates for use in the present invention include the monoclonal anti-DR5 antibodies mapatuzumab, conatumumab, lexatumumab, tigatuzumab, doroditumab, and LBY-135. Such DR5 targeted agents may be used in combination with radiolabeled HER3 targeted agents for the treatment of, for example, ovarian cancer, breast cancer, cervical cancer, prostate cancer, gastric cancer, bladder cancer, lung cancer, melanoma, colorectal cancer, and squamous cell carcinoma, as well as any of the cancers disclosed herein. Exemplary 5T4 (trophotrophoblast glycoprotein (TBPG)) targeted agents for use in the present invention, which may be radiolabeled, unlabeled, or drug conjugates, include the anti-5T4 monoclonal antibodies MED10641, ALG.APV-527, Tb535, H6-DM5, and ZV0508, as well as naptumomab estafenatox or the Fab portions thereof. Such 5T4 targeted agents may be used in combination with radiolabeled HER3 targeted agents for the treatment of, for example, ovarian cancer, head and neck cancer, breast cancer, prostate cancer, gastric cancer, bladder cancer, lung cancer, melanoma, colorectal cancer, and squamous cell carcinoma, as well as any of the cancers disclosed herein.

[0058] Exemplary HER2 (ERBB2) targeted drugs for use in the present invention, which may be radiolabeled, unlabeled, or drug conjugates, include the monoclonal antibodies trastuzumab and pertuzumab. The applicants conjugate trastuzumab with p-SCN-DOTA and the composition 225 Ac or 177Radiolabeling with Lu was successful. Exemplary ADC-targeted HER2s that can be used include fam-trastuzumab deruxtecan-nxki (Enhertu®; AstraZeneca / Daiichi Sankyo) and trastuzumab emtansine (Roche / Genentech). Anti-HER2 antibodies may also be multispecific antibodies, such as bispecific antibodies against any available HER3 / HER2 epitopes, e.g., MM-111 and MM-141 / istilazumab from Merrimack Pharmaceuticals, MCLA-128 from Merus NV, and MEHD7945A / duligotumab from Genentech. HER2-targeted drugs can be used in combination with radiolabeled HER3-targeted drugs in the treatment of HER2-expressing cancers, including but not limited to ovarian cancer, breast cancer, metastatic breast cancer, esophageal cancer, lung cancer, cervical cancer, and endometrial cancer, which are positive for both HER2 and HER3.

[0059] The amino acid sequences of the heavy and light chains of trastuzumab reported on DrugBank Online are those of the heavy chain (SEQ ID NO: 102) and the light chain (SEQ ID NO: 103), and HER2-binding antibodies containing one or both of these chains can be embodied or used in various embodiments of the present invention. The amino acid sequences of the heavy and light chains of pertuzumab reported on DrugBank Online are the heavy chain (SEQ ID NO: 104) and the light chain (SEQ ID NO: 105), and HER2-binding antibodies containing one or both of these chains can be embodied or used in various embodiments of the present invention.

[0060] Exemplary CD33-targeted drugs for use in the present invention, which may be radiolabeled, drug conjugates, or unlabeled, include the monoclonal antibodies lintuzumab, gemtuzumab, and vadastuximab. In combination with the radiolabeled HER3-targeted drugs disclosed herein, they may be used to treat solid tumors such as ovarian cancer, breast cancer, cervical cancer, prostate cancer, gastric cancer, bladder cancer, lung cancer, melanoma, colorectal cancer, and squamous cell carcinoma, as well as any of the cancers disclosed herein, for example, by depleting myeloid-derived suppressor cells (MDSCs). In one embodiment, the CD33-targeted drug used in combination with the radiolabeled HER3-targeted drug is: 225 In another embodiment, the CD33-targeted drug used in combination with a radiolabeled HER3-targeted drug is ADC gemtuzumab ozogamicin (Mylotarg®; Pfizer). Exemplary CD33-targeted drugs for use in the present invention, which may be radiolabeled, drug conjugates, or unlabeled, include anti-CD38 monoclonal antibodies such as daratumumab (Darzalex®; Johnson and Johnson) and isatuximab (Sarclisa®; Sanofi), or antigen-binding fragments thereof. Such CD38-targeted drugs may be used in combination with radiolabeled HER3-targeted drugs in the treatment of solid tumors in which CD38-positive suppressor immune cells may infiltrate, for example, ovarian cancer, breast cancer, cervical cancer, prostate cancer, gastric cancer, bladder cancer, lung cancer, melanoma, colorectal cancer, and squamous cell carcinoma, as well as any of the cancers disclosed herein.

[0061] According to aspects of the present invention, exemplary antigens (different from HER3) that can be targeted by multispecific antibodies include at least HER1 (EGFR), HER2, and IGF-1R. Exemplary HER3 multispecific targeting agents include Merrimack Pharmaceuticals' MM-111 or Merus NV's MCLA-128 (i.e., xenoctuzumab) or Merrimack Pharmaceuticals' MM-141 (i.e., istilatumab) against IGF-1R / HER3; or Roche's MEHD7945A (i.e., durigotumab) multispecific antibodies against EGFR / HER3; Zyngenia Inc.'s cetuximab-based bispecific Zybody; and Symphogen's multispecific antibody composition Sym013. See Table 2 for further description and exemplary applications. [Table 2]

[0062] The present invention also provides a method for treating a proliferative disorder or impairment, comprising administering a first antibody against at least one epitope of HER3, and administering a second antibody against an epitope of a different antigen, such as a HER3 epitope different from the first antibody, or one or more antigens selected from the list of different antigens described above. One or more of the HER3 antibodies may be radiolabeled. Antibodies against different antigens may be radiolabeled, for example, in any combination. Such combinations, presented as multispecific antibodies or two or more monoclonal antibodies as described above, can provide synergistic therapeutic effects comparable to monotherapy with antibodies against HER3 alone, while simultaneously reducing the side effects of monotherapy. Furthermore, combination therapy may improve efficacy compared to monotherapy, and this effect can be measured, for example, by a reduction in total tumor cell count, an extension of the time to recurrence, and other indicators of the patient's health. The combination therapy method includes the administration of a polyspecific antibody, wherein the first target recognition component may include, for example, one of the following: a first full-length heavy chain and a first full-length light chain, a first Fab fragment, a first single-stranded variable fragment (scFvs), or another type of antibody. The second target recognition component may include, for example, one of the following: a second full-length heavy chain and a second full-length light chain, a second Fab fragment, a second single-stranded variable fragment (scFvs), or another type of antibody. Furthermore, the second target recognition component may be derived from a different epitope of the HER3 antigen, or from any of the antigens described above.

[0063] HER3-targeted drugs may contain radioisotopes, and any additional antibodies against other antigens may optionally contain radioisotopes. In particular embodiments of the present invention, if the immunotherapy agent contains a bispecific antibody, one or both of the first target recognition component and the second target recognition component, or any portion of the bispecific targeted drug, may contain a radioisotope. According to a particular aspect of the present invention, the radiolabeled targeted drug, as a control targeted drug, exhibits essentially the same immunoreactivity to the antigen, and the control targeted drug, as a radiolabeled targeted drug, includes a naked targeted drug or otherwise unlabeled targeted drug for the same epitope of the antigen (i.e., HER3). According to a particular aspect of the present invention, the target drug is 225 It may be labeled with Ac and may be at least 5 times more effective than the control monoclonal antibody in inducing cell death in HER3-positive cells, while the control monoclonal antibody is... 225 It includes a naked or unlabeled antibody against the same antigenic epitope as the Ac-labeled antibody. For example, 225 Ac-labeled monoclonal antibodies may be at least 10 times, at least 20 times, at least 50 times, or at least 100 times more effective than control monoclonal antibodies in inducing cell death in HER3-positive cells. In particular aspects of the present invention, the method may involve the administration of labeled and unlabeled (e.g., "naked") portions of a HER3-targeting drug, such as an antibody or antibody fragment. For example, the unlabeled portion may contain the same antibody against the same epitope as the labeled portion. Thus, the total radioactivity of the antibody may be varied or kept constant, and the overall antibody protein concentration may be kept constant or varied. For example, the total protein concentration of the administered unlabeled antibody portion may vary depending on the exact nature of the disease to be treated, the patient's age and weight, the identity of the monoclonal antibody, and the label (e.g., radionuclide) selected for labeling the monoclonal antibody. According to a particular aspect of the present invention, the effective dose of the anti-HER3 antibody is the maximum tolerated dose (MTD) of the anti-HER3 antibody.

[0064] In accordance with a particular aspect of the present invention, when administering two or more antibodies, the antibodies may be administered simultaneously. For this reason, in accordance with a particular aspect of the present invention, the antibodies may be provided in a single composition. Alternatively, the two antibodies may be administered sequentially. For this reason, the radiolabeled HER3-targeted drug may be administered before the second antibody, after the second antibody, or both before and after the second antibody. Furthermore, the second antibody may be administered before the radiolabeled HER3-targeted drug, after the radiolabeled HER3-targeted drug, or both before and after the radiolabeled HER3-targeted drug. According to a particular aspect of the method of the present invention, the radiolabeled HER3-targeted drug may be administered over the course of the treatment period according to a dosing schedule selected from the group consisting of once every 7, 10, 12, 14, 20, 24, 28, 35, and 42 days, comprising at least two doses during the treatment period. According to a particular aspect of the present invention, the radiolabeled HER3-targeted drug may be administered according to a dosing schedule that includes two doses, such as on day 1 and on days 5, 6, 7, 8, 9, or 10 of the treatment period, or on day 1 and on day 8 of the treatment period.

[0065] Administration of the radiolabeled HER3-targeted drug of the present invention in addition to other therapeutic agents may be provided in several ways, depending on whether local or systemic treatment is preferred and on the area to be treated. Administration may be intratracheal, intranasal, epidermal and transdermal, oral, or parenteral. Parenteral administration may include intravenous, intra-arterial, subcutaneous, intraperitoneal, or intramuscular injection or infusion; or intracranial, e.g., intrathecal or intraventricular administration. In some embodiments, a sustained-release formulation containing the targeted drug(s) and / or other therapeutic agents may be administered. Various drugs may be administered as a single treatment or in a series of treatments continued as needed over a period of time to alleviate or improve one or more symptoms of cancer or to achieve another desired effect. The dosage(s) may vary depending, for example, on the uniqueness, size, and conditions of the subject, as well as on the route of administration of the composition and the desired effect. The appropriate dosage of a therapeutic agent varies depending on its ability to exert an effect or the activity to be regulated. The therapeutic agent may be administered to animals (e.g., humans) initially at a relatively low dose, and then the dose may be increased until an appropriate response is obtained. Radiolabeled HER3-targeted drugs may be administered concurrently or sequentially with one or more additional therapeutic agents. Furthermore, if two or more additional therapeutic agents are included, these additional therapeutic agents may be administered concurrently or sequentially with each other and / or with the radiolabeled HER3-targeted drug.

[0066] Radiolabeling HER3-targeted drugs The HER3-targeted drugs and other targeted drugs disclosed herein are, for example, β-radiators (e.g., by conjugation of chelating agent molecules and chelation of radioisotopes thereto) 177 Lu) or alpha emitters (for example, 225It can be labeled with radioisotopes such as Ac). In a particular embodiment, the target drug may be an antibody against a substance that has been deglycosylated at a constant region such as asparagine 297 (Asn-297, N297; Kabat number) in the heavy chain CH2 domain, for the purpose of finding the specific conjugation site of glutamine (i.e., Gln-295, Q295), thereby making it available for conjugation with a bifunctional chelating agent molecule. In a particular embodiment, the radiotherapy agent may be an antibody in which disulfide bonds have been reduced by the use of a reducing agent or the like, and then converted to dehydroalanine for the purpose of conjugating with a bifunctional chelating agent molecule. In a particular embodiment, the radiotherapy agent may be an antibody in which disulfide bonds have been reduced using a reducing agent, and then conjugated with a bifunctional chelating agent molecule by aryl crosslinking. For example, in a particular embodiment, free sulfhydryl groups on the antibody can be crosslinked using a linker molecule such as 3,5-bis(bromomethyl)benzene.

[0067] In a particular embodiment, the radiotherapy agent may be an antibody in which a specific existing amino acid is replaced with cysteine(s) which can later be used for site-specific labeling. Exemplary chelating agents that can be conjugated to target drugs in various aspects of the present invention include: 1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid (DO3A) or derivatives thereof; 1,4,7-triazacyclononane-1,4-diacetic acid (NODA) or derivatives thereof; 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA) or derivatives thereof; 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) or derivatives thereof; 1,4,7-triazacyclononane, 1-glutaric acid -4,7-diacetic acid (NODAGA), or derivatives thereof; 1,4,7,10-tetraazacyclodecane, 1-glutaric acid-4,7,10-triacetic acid (DOTAGA), or derivatives thereof; 1,4,8,11-tetraazacyclotetradecane-1,4,8,11-tetraacetic acid (TETA), or derivatives thereof; 1,4,8,11-tetraazabicyclo[6.6.2]hexadecane-4,11-diacetic acid (CB-TE2A), or derivatives thereof; diethylenetriaminepentaacetic acid (DTPA), its diester, or derivatives thereof; 2- Chlohexyldiethylenetriaminepentaacetic acid (CHX-A''-DTPA) or derivatives thereof; deferoxamine (DFO) or derivatives thereof; 1,2-[[6-carboxypyridine-2-yl]methylamino]ethane (H2-dodopa) or derivatives thereof; DADA or derivatives thereof; 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetra(methylenephosphonic acid) (DOTP) or derivatives thereof; 4-amino-6-[[16-[(6-carboxypyridine-2-yl) [Methyl]-1,4,10,13-tetraoxa-7,16-diazacyclooctadec-7-yl]methyl]pyridine-2-carboxylic acid (MACROPA-NH2) or derivatives thereof; MACROPA or derivatives thereof; 1,4,7,10-tetrakis(carbamoylmethyl)-1,4,7,10-tetraazacyclododecane (TCMC) or derivatives thereof; {4-[2-(bis-carboxymethylamino)-ethyl]-7-carboxymethyl-[1,4,7]triazonan-1-yl}acetic acid (NETA) or derivatives thereof;Diamsar or derivatives thereof; 1,4,7-Triazacyclononanane-1,4,7-tri[methyl(2-carboxyethyl)phosphinic acid (TRAP, PRP9, TRAP-Pr) or derivatives thereof; N,N'-Bis(6-carboxy-2-pyridylmethyl)ethylenediamine-N,N'-diacetic acid (H4 octapa) or derivatives thereof; N,N'-[1-benzyl-1,2,3-triazole-4-yl]methyl-N,N'-[ 6-(carboxy)pyridine-2-yl]-1,2-diaminoethane (H2 azapa) or derivatives thereof; N,N''-[[6-(carboxy)pyridine-2-yl]methyl]diethylenetriamine-N,N',N''-triacetic acid (H5 decapa) or derivatives thereof; N,N'-bis(2-hydroxy-5-sulfobenzyl)ethylenediamine-N,N'-diacetic acid (SHBED) or derivatives thereof; N,N'-bis(2-hydroxybenzyl) Ethylenediamine-N,N'-diacetic acid (HBED) or derivatives thereof; 3,6,9,15-Tetraazabicyclo[9.3.1]pentadeca-1(15),11,13-triene-3,6,9,-triacetic acid (PCTA) or derivatives thereof; Desferrioxamine B (DFO) or derivatives thereof; N,N'-(methylenephosphonate)-N,N'-[6-(methoxycarbonyl)pyridine-2-yl]methyl-1,2-diamine Noethane (H6 phosphine) or derivatives thereof; 1,4,7,10,13,16-Hexazacyclohexadecane-N,N',N'',N''',N'''',N'''''-Hexaacetic acid (HEHA) or derivatives thereof; 1,4,7,10,13-Pentazacyclopentadecane-N,N',N'',N''',N''''-Pentaacetic acid (PEPA) or derivatives thereof; or 3,4,3-LI(1,2-HOPO) or derivatives thereof.

[0068] In a particular embodiment, the target may be radiolabeled by chemical conjugation of a suitable bifunctional chelating agent capable of chelating one or more radionuclides. Examples of chelating agent molecules that can be used include p-SCN-Bn-DOTA, NH2-DOTA, and NH2-(CH2) 1-20 -DOTA, NH2-(PEG)1-20 -DOTA, HS-DOTA, HS-(CH2) 1-20 -DOTA, HS-(PEG) 1-20 -DOTA, Zibrom-S-(CH2) 1-20 -DOTA, Zibromo-S-(PEG) 1-20 -DOTA, p-SCN-Bn-DOTP, NH2-DOTP, NH2-(CH2) 1-20 -DOTP, NH2-(PEG) 1-20 -DOTP, HS-DOTP, HS-(CH2) 1-20 -DOTP, HS-(PEG) 1-20 -DOTP, Dibromo-S-(CH2) 1-20 -DOTP and dibromo-S-(PEG) 1-20 -DOTP exists. Chelating agent molecules can bind to the target drug, for example, via linker molecules. Exemplary linker molecules include: -CH2(C6H4)NH2 or -CH2(C6H4)NH-XY, In the equation, X is -R2-CH2CH2O(CH2CH2O) n CH2CH2-, -R2-CH2CH2NHC(O)CH2CH2O(CH2CH2O) n CH2CH2-, -R2-(CH2) n CH2-, -R2-CH2CH2NHC(O)(CH2) n CH2-, -R2-CH(C(O)R3)CH2-, where R3 is -OH or a short-chain peptide (1 to 20 amino acids). -R2-CH2CH2O(CH2CH2O) n CH2C(O)O-, or -R2-CH2CH2NHC(O)CH2CH2O(CH2CH2O) n CH2CC(O)O-, In the formula, n is 1 to 20, and R2 is -C(O)- or -C(S)NH-; and Y is either -NH2 or -SR 4-In the formula, R4 is -H or -CH2-3,5-bis(bromomethyl)benzene.

[0069] Targeted drugs such as protein-targeted drugs, e.g., antibodies and antigen-binding antibody fragments, and peptide-targeted drugs, can be conjugated with chelating agents for radiolabeling the target drug by chelation of a radionuclide. For example, such protein or peptide-targeted drugs containing lysine(s) can be conveniently conjugated to a DOTA that chelates the portion using the bifunctional agent S-2-(4-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecanetetraacetic acid, also known as "p-SCN-Bn-DOTA" (catalog number: B205; Macrocyclics, Inc., Plano, Texas, USA). p-SCN-Bn-DOTA can be synthesized by a multi-step organic synthesis described in detail in U.S. Patent No. 4,923,985. Chelation of the radionuclide by the DOTA portion can be carried out before and / or after the chemical conjugation of the antibody with p-SCN-Bn-DOTA. A method for labeling a target drug conjugated with a chelating agent with an exemplary radionuclide is described in Example 1.

[0070] Diagnostic methods The methods disclosed herein may include diagnosing a subject to determine the presence, extent, and / or localization of HER3-positive cells. HER3-positive cells may be present in numerous biological samples, such as circulating cells in a blood sample of a subject or tumor cells during a biopsy of a subject. In one embodiment, the diagnostic step may generally include collecting a blood or tissue sample of the subject and placing the sample on a substrate. The presence or absence of the HER3 antigen may be detected using a diagnostic antibody, peptide, or small molecule, the diagnostic antibody peptide, or small molecule being labeled with one of the standard imaging labels known in the art. Exemplary labeling agents include, for example, radiolabeling, e.g., 3 H, 14 C, 32 P, 35 S, and 125I; fluorescent or chemiluminescent compounds, such as fluorescein isothiocyanate, rhodamine, or luciferin; and enzymes, such as alkaline phosphatase, β-galactosidase, or horseradish peroxidase. Exemplary HER3-targeted drugs used in such diagnostic assays include human or humanized antibodies against HER3.

[0071] In another embodiment, the method involves radionuclides, for example, for PET imaging. 18 F, 11 C, 68 Ga, 64 Cu, 89 Zr, or 124 For I or SPECT imaging 99m Tc or 111 The method may include diagnosing a subject to confirm the presence of HER3-positive cells using a HER3-targeted drug labeled with one of the Ins. 18 F, 11 C, 68 Ga, 64 Cu, 89 Zr, 124 I, 99m Tc, or 111 The method may include administering a HER3-targeted drug labeled with one or more of the Ins to a target, and performing the procedure with non-invasive imaging techniques, such as PET or SPECT scans. The method may include administering a radiolabeled HER3-targeted drug for imaging to a target, and performing imaging after sufficient time for the target drug to bind to the target in the target tissue. Sufficient time for the target drug to bind to the target in the target tissue may be, for example, at least 20 minutes, at least 30 minutes, at least 60 minutes, or any number or sub-range of minutes within the range of 20 to 360 minutes. According to a particular aspect of the present invention, the radiolabeled HER3-targeted drug is 68 Ga, 89 Zr, or 111 It may contain In and may be labeled using any of the methods disclosed herein (for example, disclosed in Example 1). The therapeutic methods of the present invention disclosed herein may be implemented when the subject has, for example, HER3-positive cancer cells exceeding a predetermined or pre-selected threshold level, or other signs of HER3-positive cancer / tumor. That is, a therapeutically effective dose of a radiolabeled HER3-targeted drug may be administered alone or in combination with one or more additional therapeutic agents.

[0072] Additional medications and treatment methods The methods of the present invention, which include the administration of a radiolabeled HER3-targeted drug alone or in combination with other targeted drugs, may further include additional therapeutic agents or forms of administration. Depending on the particular embodiment, the additional agents may be appropriate for the disease or condition being treated with the radiolabeled HER3-targeted drug. Such administrations may be concurrent, separate, or sequential with an effective dose of the HER3-targeted drug. In concurrent administrations, the agents may be administered as a single composition or as separate compositions, as necessary. Exemplary additional therapeutic agents and forms that may be used in combination with or together with radiolabeled HER3-targeted agents include, at a minimum, chemotherapeutic agents, small molecule antitumor agents, anti-inflammatory agents, immunosuppressants, immunomodulators, immune checkpoint agents, DDR inhibitors, CD47 blockers, external beam radiation therapy, brachytherapy, or any combination thereof. Exemplary additional agents that may be used alone or in combination with or together with radiolabeled HER3-targeted agents disclosed herein are further described below.

[0073] A. Chemotherapy drugs and other small molecule drugs Examples of chemotherapeutic agents include, but are not limited to, antitumor drugs containing alkylating agents such as: nitrogen mustards, e.g., mechloretamine, cyclophosphamide, ifosfamide, melphalan, and chlorambucil; nitrosoureas, e.g., carmustine (BCNU), lomustine (CCNU), and semustine (methylCCNU); Temodal® (temozolamide), ethyleneimine / methylmelamine, e.g., triethylenemelamine (TEM), triethylene methyl Phosphoramides (thiotepa), hexamethylmelamine (HMM, altretamine); alkyl sulfonates, e.g., busulfan; triazines, e.g., dacarbazine (DTIC); antimetabolites including folic acid analogs, e.g., methotrexate and trimethrexate; pyrimidine analogs, e.g., 5-fluorouracil (5FU), fluorodeoxyuridine, gemcitabine, cytosine arabinoside (AraC, cytarabine), 5-azacitidine, 2,2'-difluorodeoxycytidine, pr Vinca alkaloids, such as 6-mercaptopurine, 6-thioguanine, azathiopurine, T-deoxycoformycin (pentostatin), erythrohydroxynonyladenine (EHNA), fludarabine phosphate, and 2-chlorodeoxyadenosine (cladribine, 2-CdA); natural products containing cell division inhibitors, such as paclitaxel, vinblastine (VLB), vincristine, and vinorelbine; taxotere, estramustine; and Estramustine phosphate; pipodophyllotoxins, e.g., etoposide and teniposide; antibiotics, e.g., actinomycin D, daunomycin (rubidomycin), doxorubicin, mitoxantrone, idarubicin, bleomycin, plicamycin (mitramycin), mitomycin C, and actinomycin; enzymes, e.g., L-asparaginase; biological reaction modifiers, e.g., interferon α, IL-2, G-CSF, and GM-CSF;Various drugs containing platinum complex compounds, e.g., oxaliplatin, cisplatin, and carboplatin; anthracendiones, e.g., mitoxantrone; substituted ureas, e.g., hydroxyurea; methylhydrazine derivatives including N-methylhydrazine (MIH) and procarbazine; adrenal cortical inhibitors, e.g., mitotane (o,p-DDD) and aminoglutethimide; hormones, and antagonists including adrenal cortical hormone antagonists, e.g., prednisolone and its equivalents; dexamethasone; and aminoglutethimide; Gemzar (registered trademark) (Gemzar) Mucitabine), progestins, e.g., hydroxyprogesterone caproate, medroxyprogesterone acetate, and megestrol acetate; estrogens, e.g., diethylstilbestrol and ethinylestradiol equivalents; antiestrogens, e.g., tamoxifen; androgens, including testosterone propionate and fluoxymesterone / equivalents; antiandrogens, e.g., flutamide, gonadotropin-releasing hormone analogs, and leuprolide; and nonsteroidal antiandrogens, e.g., flutamide.

[0074] (i) Histone deacetylase (HDAC) inhibitors, e.g., vorinostat (sveroylanilide hydroxamic acid; SAHA), romidepsin, bellinostat (PDX101), panobinostat (LBH589), and tucidinostat, demethylating agents (e.g., Vidaza); (ii) LSD1 inhibitors, e.g., secridemstat, TCP (tranylcypromine), ORY-1001 (idademstat), GSK2879552 (GSK), INCB059872 (Imago BioSciences), IMG-7289 (bomedemstat; Imago Therapeutic agents targeting epigenetic mechanisms, including but not limited to BioSciences, ORY-2001 (bafidemstat), and CC-90011 (Celgene); and (iii) transcriptional repression deactivation (ATRA) therapies, may also be used in combination with or together with radiolabeled HER3-targeted agents and / or other radiolabeled-targeted agents and combinations thereof as described herein. According to a particular aspect of the present invention, the chemotherapeutic agent comprises at least a radiosensitizer such as temozolomide, cisplatin, and / or fluorouracil.

[0075] Additional agents may include, for example, bcl-2 inhibitors such as navitoclax or venetoclax (Veneclexta®; Abbvie), and this combination may be used, for example, to treat solid tumors such as breast cancer and lung cancer such as small cell lung cancer (SCLC). Additional agents may include, for example, cyclin-dependent kinase CDK4 and CDK6 inhibitors, such as palbociclib (Ibrance®; Pfizer), and this combination may be used, for example, with or without aromatase inhibitors, to treat solid tumors such as breast cancer, including HR-positive and HER2-negative breast cancer. Additional agents may include, for example, erlotinib (Tarceva®; Roche), and this combination may be used, for example, to treat solid tumor cancers such as non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations and pancreatic cancer. Additional drugs may include, for example, sirolimus or everolimus (Afinitor®; Novartis), and this combination may be used, for example, to treat solid tumor cancers such as melanoma and breast cancer. Additional drugs may include, for example, pemetrexed (Alimta®; Eli Lilly), and this combination may be used to treat solid tumors such as mesothelioma, including pleural mesothelioma, and lung cancer, including non-small cell lung cancer (NSCLC). Additional therapeutic agents may be administered, for example, according to standard dosing regimens known in the art. For example, the therapeutic agent may be administered at doses of 1 to 500 mg / m². 2 It can be administered at concentrations within the range of (the amount is the patient's surface area (m²) 2 (Calculated as a function of ). For example, exemplary doses of the chemotherapy drug paclitaxel range from 15 to 275 mg / m². 2 It may contain, and an example dose of docetaxel is 60-100 mg / m². 2It may contain, and an example dose of epithirone is 10-20 mg / m². 2 It may contain, and an example dose of calitiamycin is 1-10 mg / m². 2 This specification may include the following. While exemplary dosages are provided herein, they are for reference only and are not intended to limit the dosage range of the agents of the present invention disclosed herein.

[0076] B. External beam radiation therapy and / or brachytherapy Additional therapies administered in conjunction with HER3-targeted drugs and, optionally, any other additional therapeutic agents disclosed herein, may be ionizing radiation delivered by external beam radiation or brachytherapy. Such radiotherapy generally refers to generating ionizing radiation using X-rays, gamma rays, or charged particles (e.g., protons or electrons) that are delivered from a machine placed outside the patient's body (external beam radiation therapy) or from a source placed inside the patient's body (internal radiation therapy or brachytherapy). External beam radiation therapy or brachytherapy may enhance the targeted radiation damage delivered by radiolabeled HER3-targeted drugs and can therefore be delivered sequentially with or concurrently with HER3-targeted drugs, such as before and / or after the HER3-targeted drug. External beam radiation therapy or brachytherapy can be planned and administered in conjunction with imaging-based techniques such as computed tomography (CT) and / or magnetic resonance imaging (MRI) to accurately determine the dose and location of radiation to be administered. For example, a patient treated with any of the radiolabeled HER3-targeted drugs disclosed herein can be imaged using either CT or MRI to determine the dose and location of radiation to be administered by external beam radiation therapy or brachytherapy.

[0077] In various embodiments, radiotherapy may be selected from the group consisting of whole-body radiotherapy, conventional external beam radiotherapy, stereotactic radiotherapy, stereotactic body radiotherapy, three-dimensional conformal radiotherapy, intensity-modulated radiotherapy, image-guided radiotherapy, tomotherapy, and brachytherapy. Depending on the particular embodiment, radiotherapy may be delivered as a single dose or as fractionated doses, for example, divided into two or more doses. For example, this dose may be administered such that each dose contains 2 to 20 Gy (for example, a 50 Gy radiation dose may be divided into 10 doses, each containing 5 Gy). Two or more fractionated doses may be administered on consecutive days, or on a continuous schedule such as every two days, every three days, every four days, every five days, every six days, every seven days, or a combination thereof.

[0078] C. Immunotherapy drugs Additional drugs administered alongside HER3-targeted therapies may be immune checkpoint therapies. Cancer cells have developed mechanisms to evade standard checkpoints of the immune system. For example, cancer cells are known to evade immune surveillance by reducing the expression of tumor antigens, downregulating MHC class I and II molecules that lead to reduced presentation of tumor antigens, secreting immunosuppressive cytokines such as TGFb, recruiting or inducing immunosuppressive cells such as regulatory T cells (Treg) or myeloid-derived suppressor cells (MDSCs), and overexpressing certain ligands that suppress the host's existing anti-tumor immunity [e.g., programmed death ligand-1 (PD-L1)]. Another major immunosuppressive mechanism by cancer cells is a process known as "T cell depletion," which results from chronic exposure to tumor antigens and is characterized by the upregulation of inhibitory receptors. These inhibitory receptors function as immune checkpoints to prevent uncontrolled immune responses. Various immune checkpoints that act at different levels of T cell immunity are described in the literature, including PD-1 (i.e., programmed cell death protein 1) and its ligands PD-L1 and PD-L2, CTLA4 (i.e., cytotoxic T lymphocyte-associated protein 4) and its ligands CD80 and CD86, LAG3 (i.e., lymphocyte activation gene 3), B and T lymphocyte atenuators, TIGIT (T cell immune receptor with Ig and ITIM domains), TIM-3 (i.e., T cell immunoglobulin and mucin domain-containing protein 3), and VISTA (V-domain immunoglobulin suppressor for T cell activation).

[0079] The enhancement of immune system effects through therapeutic intervention is a particularly welcome development in cancer treatment. As demonstrated, checkpoint inhibitors such as CTLA-4 and PD-1 prevent autoimmunity and generally protect tissues from adverse immune damage. In addition, stimulating checkpoints such as OX40 (i.e., tumor necrosis factor receptor superfamily member 4; TNFR-SF4), CD137 (i.e., TNFR-SF9), GITR (i.e., glucocorticoid-inducible TNFR), CD27 (i.e., TNFR-SF7), CD40 (i.e., differentiation antigen group 40), and CD28 activate and / or promote T cell proliferation. Modulation of the immune system by suppression or overexpression of these proteins is currently a promising area of ​​research. Therefore, a promising therapeutic strategy involves combining HER3-targeted drugs disclosed herein with immune checkpoint therapies that can remove specific blockages in the immune system utilized by cancer cells. For example, antibodies against certain immune checkpoint inhibitors (ICIs) can block the interaction between checkpoint inhibitor proteins and their ligands, thereby interfering with signaling events that would normally inhibit the immune response against tumor cells. Furthermore, there is growing preclinical evidence supporting the ability of radiation to synergistically interact with ICI antibodies. This is also being investigated clinically, with an increasing number of clinical trials evaluating the combination of external beam radiation and immune checkpoint therapy across various tumor types and ICI antibodies (Lamichhane, 2018). Clinical evidence supporting this combination has been obtained in melanoma in two trials demonstrating the clinical utility of combining the anticytotoxic T lymphocyte-associated protein 4 (CTLA-4) ICI antibody ipilimumab with radiation (Twyman-Saint Vistor, 2015). Accordingly, an object of the present invention disclosed herein is to provide a cancer treatment using a HER3-targeted drug in combination with one or more immune checkpoint therapeutic agents such as ICI antibodies.

[0080] The immune checkpoint therapeutics of the present invention comprise molecules that completely or partially reduce, suppress, inhibit, or modulate one or more checkpoint proteins. Checkpoint proteins regulate the activation or function of T cells. The immune checkpoint therapeutics can relieve existing suppression of the immune response by binding to or otherwise neutralizing checkpoint suppression. The immune checkpoint therapeutics may comprise monoclonal antibodies, humanized antibodies, fully human antibodies, antibody fragments, small molecule therapeutics, or combinations thereof. Exemplary immune checkpoint therapies can specifically bind to and suppress checkpoint proteins such as the inhibitory receptors CTLA-4, PD-1, TIM-3, VISTA, BTLA, LAG-3, and TIGIT, and / or the activating receptors CD28, OX40, CD40, GITR, CD137, CD27, and HVEM. Furthermore, immune checkpoint therapies can bind to ligands of any of the aforementioned checkpoint proteins, such as PD-L1, PD-L2, PD-L3, and PD-L4 (ligands of PD-1); CD80 and CD86 (ligands of CTLA-4); CD137-L (ligand of CD137); and GITR-L (ligand of GITR). Other exemplary immune checkpoint therapies may bind to checkpoint proteins such as CD226, B7-H3, B7-H4, BTLA, TIGIT, GALS, KIR, 2B4 (belonging to the CD2 family of molecules and expressed on all NK, γδ, and memory CD8+(αβ) T cells), CD160 (also known as BY55), and CGEN-15049.

[0081] The core of the immune checkpoint process is the CD137, CTLA-4, and PD-1 immune checkpoint pathways. The CTLA-4 and PD-1 pathways are thought to function at different stages of the immune response. CTLA-4 is considered a “leader” of immune checkpoint inhibitors (ICIs) because it typically occurs in lymph nodes, arsenting potentially autoreactive T cells in the early stages of naive T cell activation. The PD-1 pathway controls already activated T cells in the later stages of the immune response, primarily in peripheral tissues. Furthermore, it has been shown that PD-L1 upregulation by either tumor cells or tumor-infiltrating immune cells is less pronounced in patients with advanced cancer. Therefore, immune checkpoint therapies targeting the PD-1 pathway may be particularly effective in tumors where this immunosuppressive axis is functioning, potentially reactivating and enhancing the existing anti-tumor immune response by reversing the balance towards an immunoprotective environment. Blockade of PD-1 can be achieved through various mechanisms, including antibodies that bind to PD-1 or its ligand, PD-L1.

[0082] In accordance with certain aspects of the present invention disclosed herein, immune checkpoint therapeutics may include PD-1 checkpoint inhibitors that can reduce, block, suppress, or inhibit signaling resulting from the interaction of PD-1 with one or more of its binding partners, such as PD-L1 and PD-L2. PD-1 checkpoint inhibitors may be anti-PD-1 antibodies, antigen-binding fragments, fusion proteins, oligopeptides, and other molecules that reduce, block, suppress, inhibit, or inhibit signaling resulting from the interaction of PD-1 with PD-L1 and / or PD-L2. In some embodiments, PD-1 checkpoint inhibitors reduce negative costimulatory signals mediated by or through cell surface proteins expressed on T lymphocytes, thereby reducing the dysfunction of dysfunctional T cells (e.g., enhancing the effector response to antigen recognition). In some embodiments, the PD-1 checkpoint therapeutic is an anti-PD-1 antibody. Accordingly, according to certain aspects of the present invention, an immune checkpoint therapeutic agent may include a monoclonal antibody against an immune checkpoint inhibitor (ICI), such as CTLA-4, PD-1, or PD-L1. In certain embodiments, an ICI antibody may be an antibody against PD-1. An ICI antibody may be an anti-PD-1 antibody such as nivolumab. For example, there are inhibitors of PD-1 biological activity (or its ligand) disclosed in U.S. Patent No. 7,029,674. Exemplary antibodies against PD-1 include: BioXcell's anti-mouse PD-1 antibody clone J43 (catalog number: BE0033-2); BioXcell's anti-mouse PD-1 antibody clone RMP1-14 (catalog number: BE0146); mouse anti-PD-1 antibody clone EH12; Merck's MK-3475 anti-mouse PD-1 antibody (Keytruda®, pembrolizumab, lambrolizumab); AnaptysBio's anti-PD-1 antibody (also known as ANB011); antibody MDX-1 106 (ONO-4538); Bristol-Myers Squibb's human IgG4 monoclonal antibody nivolumab (Opdivo®, BMS-936558, MDX1106); AstraZeneca's AMP-514 and AMP-224; and CureTech Ltd.'s pidilizumab (CT-011).

[0083] In certain embodiments, immune checkpoint therapeutics are PD-L1 inhibitors. Exemplary PD-L1 inhibitors include antibodies (e.g., anti-PD-L1 antibodies, i.e., ICI antibodies), RNAi molecules (e.g., anti-PD-L1 RNAi), antisense molecules (e.g., anti-PD-L1 antisense RNA), dominant-negative proteins (e.g., dominant-negative PD-L1 proteins), and small molecule inhibitors. An example of an anti-PD-L1 antibody is clone EH12. Examples of antibodies against PD-L1 include: Genentech's MPDL3280A (RG7446); BioXcell's anti-mouse PD-L1 antibody clone 10F.9G2 (catalog number: BE0101); Bristol-Meyer's Squibb's anti-PD-L1 monoclonal antibody MDX-1105 (BMS-936559) and BMS-935559; MSB0010718C; mouse anti-PD-L1 clone 29E.2A3; and AstraZeneca's MEDI4736 (durvalumab). In certain embodiments, immune checkpoint therapeutics are PD-L2 inhibitors or may reduce the interaction between PD-1 and PD-L2. Exemplary PD-L2 inhibitors include antibodies (e.g., anti-PD-L2 antibodies, i.e., ICI antibodies), RNAi molecules (e.g., anti-PD-L2 RNAi), antisense molecules (e.g., anti-PD-L2 antisense RNA), dominant-negative proteins (e.g., dominant-negative PD-L2 proteins), and small molecule inhibitors. Antibodies include monoclonal antibodies, humanized antibodies, deimmunized antibodies, and Ig fusion proteins. In certain embodiments, immune checkpoint therapeutics may be CTLA-4 inhibitors, i.e., ICI antibodies, such as anti-CTLA-4 antibodies. In one embodiment, the ICI antibody may be ipilimumab. Anti-CTLA-4 antibodies can block the binding of CTLA-4 to CD80(B7-1) and / or CD86(B7-2) expressed on antigen-presenting cells. Exemplary antibodies against CTLA-4 include: Bristol Meyers Squibb's anti-CTLA-4 antibody ipilimumab (also known as Yervoy®, MDX-010, BMS-734016, and MDX-101); Millipore's anti-CTLA4 antibody clone 9H10; Pfizer's tremelimumab (CP-675,206, tisilimmab); and Abcam's anti-CTLA-4 antibody clone BNI3. In certain embodiments, immune checkpoint inhibitors may be nucleic acid inhibitors of CTLA-4 expression.

[0084] CD137 (also known as "TNF receptor superfamily member 9") is a costimulatory receptor member of the tumor necrosis factor receptor superfamily that mediates CD28-dependent and independent T cell costimulation (Bartkowiak, 2015). CD137 is inductively expressed by T cells, natural killer (NK) cells, dendritic cells (DCs), B cells, and other cells of the immune system. This protein consists of a 255 amino acid protein with a short N-terminal cytoplasmic portion, a transmembrane region, and an extracellular domain with three cysteine-rich motifs. When CD137 is ligated by its ligand CD137L (4-1BBL; TNFSF9), which is expressed not exclusively but primarily on antigen-presenting cells (APCs), various T cell responses are triggered, including cell proliferation, increased cytokine secretion, and inhibition of activation-induced cell death. Thus, such ligation plays a role in activating the immune system. However, the cis-interaction between CD137 and CD137L also strongly downregulates CD137L expression (Kwon, 2015). Therefore, CD137 ligands function to control the degree and dynamics of CD137-mediated immune system activation (Kwon, 2015). Importantly, CD137 expressed on human NK cells is upregulated when it binds to antitumor antibodies bound to tumor cells (Wei, 2014).

[0085] Accordingly, according to certain aspects of the present invention disclosed herein, an immune checkpoint therapeutic agent may comprise an antibody against CD137, which can be used to activate the immune system and thereby provide cancer treatment in combination with the HER3-targeted drugs disclosed herein. Exemplary anti-CD137 antibodies that may be used are described in U.S. Patent Publication Nos. 20140274909;20130280265;20130273078;20130071403;20120058047;20110104049;20110097313;20080166336;20080019905;20060188439;20060182744;20060121030; and 20030223989. According to a particular aspect of the present invention, an immune checkpoint therapeutic agent may comprise two or more modulators of immune checkpoint proteins. Thus, the immune checkpoint therapeutic agent may comprise a first antibody or inhibitor against a first immune checkpoint protein and a second antibody or inhibitor against a second immune checkpoint protein.

[0086] D. DNA damage response inhibitors Additional agents administered alongside HER3-targeted therapies may be one or more DNA damage response inhibitors (DDRi). DNA damage can be caused by intrinsic factors such as spontaneous reactions, enzymatic reactions, chemical reactions, or replication errors, or by exogenous factors such as UV or ionizing radiation or genetically modified chemicals. The repair pathways that overcome this damage are collectively referred to as the DNA damage response or DDR. This signaling network acts to detect and organize the cell's response to specific forms of DNA damage, particularly double-strand breaks and replication stress. After treatment with a variety of DNA-damaging agents and ionizing radiation, cells rely on DDR for survival. It has been shown that disrupting DDR can increase the sensitivity of cancer cells to these DNA-damaging agents, thereby potentially improving the patient's response to such therapies. DNA repair mechanisms (DDR) include several mechanisms, including base excision repair, nucleotide excision repair, mismatch repair, homologous recombination repair, and non-homologous end joining. Approximately 450 human DDR genes encode proteins that function in physiological processes. Dysregulation of DDR can lead to a variety of disorders, including hereditary, neurodegenerative, immune, cardiovascular, and metabolic diseases or disorders, and cancer. For example, the genes OGG1 and XRCC1 are part of the DDR base excision repair mechanism, and mutations in these genes are found in kidney cancer, breast cancer, and lung cancer, while the genes BRCA1 and BRCA2 are involved in homologous recombination repair, and mutations in these genes increase the risk of breast cancer, ovarian cancer, prostate cancer, and pancreatic cancer, as well as gastrointestinal cancers, hematological cancers, and melanoma. Exemplary DDR genes are listed in Table 3.

[0087] An object of the present invention disclosed herein is to administer a radiolabeled HER3-targeted drug that delivers ionizing radiation in combination with DDRi. Accordingly, an additional drug(s) administered in combination with the HER3-targeted drug according to a particular embodiment may target the DDR protein (i.e., a DDR inhibitor or DDRi) and thereby maximize DNA damage or inhibit repair in the case of DNA damage in the G1 and S phases, and / or block repair in the case of G2 phase, so that the maximum amount of DNA damage enters mitosis and can lead to cell death. [Table 3] Furthermore, one or more DDR pathways may be targeted to ensure cell death, i.e., lethality to target cancer cells. For example, mutations in the BRCA1 and BRCA2 genes alone may not be sufficient to ensure cell death because other pathways, such as the PARP1 base excision pathway, may act to repair DNA damage. Therefore, combinations of multiple DDRi inhibitors, or combinations of DDRi with angiogenesis inhibitors or immune checkpoint inhibitors as described above, are possible and constitute the object of the present invention disclosed herein.

[0088] Exemplary DDRi-ATM and ATR inhibitors Ataxia telangiectasia mutations (ATM) and Ataxia telangiectasia mutations and Rad3-associated mutations (ATR) are members of the phosphatidylinositol 3-kinase-associated kinase (PIKK) family of serine / threonine protein kinases. ATM is a serine / threonine protein kinase that is recruited and activated by DNA double-strand breaks. ATM phosphorylates several key proteins that initiate the activation of DNA damage checkpoints, leading to cell cycle arrest, DNA repair, or cellular apoptosis. Some of these targets, including p53, CHK2, and H2AX, are tumor suppressors. The name of this protein comes from Ataxia telangiectasia mutations, a disease caused by mutations in ATM. ATM belongs to the phosphatidylinositol 3-kinase-related kinase (PIKK) superfamily, which includes six serine / threonine protein kinases that exhibit sequence similarity to phosphatidylinositol 3-kinase (PI3K). Like ATM, ATR is one of the central kinases involved in DDR. ATR is activated by single-stranded DNA structures, which can occur, for example, in excised DNA DSBs or stalled replication forks. When DNA polymerase stalls during DNA replication, replication helicase continues to unwind the DNA before the replication fork, producing long single-stranded DNA (ssDNA).

[0089] ATM is known to help cancer cells by inducing resistance to chemotherapy drugs, thereby promoting tumor growth and survival. Inhibiting ATM and / or ATR can significantly improve the sensitivity of cancer cells to DNA damaging agents such as ionizing radiation induced by radiolabeled HER3-targeted drugs. Accordingly, an object of the present invention disclosed herein is to administer ATM inhibitors (ATMi) and / or ATR inhibitors (ATRi) in combination with HER3-targeted drugs to suppress or kill cancer cells that express or overexpress HER3. ATM inhibitors (ATMi) or ATR inhibitors (ATRi) may be antibodies, peptides, or small molecules that target ATM or ATR, respectively. Alternatively, ATMi or ATRi may reduce or eliminate the activation of ATM or ATR by one or more signaling molecules, proteins, or other compounds, or they may result in the reduction or elimination of ATM or ATR activation by all of these signaling molecules, proteins, or other compounds. ATMi and / or ATRi also include compounds that suppress their expression (e.g., compounds that suppress the transcription or translation of ATM or ATR). Exemplary ATMi KU-55933 suppresses cell proliferation and induces apoptosis. Other exemplary ATMi include, at least, KU-59403, woltmannin, CP466722, and KU-60019. Exemplary ATRi include at least cisandrin B, NU6027, NVP-BEA235, VE-821, VE-822, AZ20, and AZD6738.

[0090] Exemplary DDRi-Wee1 inhibitors The checkpoint kinase Wee1 catalyzes the inhibitory phosphorylation of both CDK1 (CDC2) and CDK2 at tyrosine 15, thereby arranging the cell cycle in response to exogenously induced DNA damage. Deregulation of Wee1 expression or activity is thought to be a characteristic pathological feature in several cancer types. For example, Wee1 is often overexpressed in glioblastoma, malignant melanoma, hepatocellular carcinoma, breast cancer, colon cancer, lung cancer, and head and neck squamous cell carcinoma. In advanced tumors with elevated levels of genomic instability, functional checkpoints that enable the repair of such lethal DNA damage may be necessary. For this reason, we believe that Wee1 is an attractive target in advanced tumors where inhibition is thought to result in irreparable DNA damage. Accordingly, an object of the present invention disclosed herein is to administer a Wee1 inhibitor in combination with a HER3-targeted drug to suppress or kill cancer cells that express or overexpress HER3. Wee1 inhibitors may be antibodies, peptides, or small molecules that target Wee1. Alternatively, Wee1 inhibitors may reduce or eliminate Wee1 activation by one or more signaling molecules, proteins, or other compounds, or they may cause a reduction or elimination of Wee1 activation by all of these signaling molecules, proteins, or other compounds. This term also includes compounds that reduce or eliminate the activation or inactivation of one or more proteins or cellular signaling components by Wee1 (for example, Wee1 inhibitors may reduce or eliminate Wee1-dependent inactivation of cyclin and Cdk activity). Wee1 inhibitors also include compounds that suppress Wee1 expression (for example, compounds that suppress Wee1 transcription or translation).

[0091] Exemplary Wee1 inhibitors include AZD-1775 (i.e., adavocertib), as well as, for example, U.S. 7,834,019; 7,935,708; 8,288,396; 8,436,004; 8,710,065; 8,716,297; 8,791,125; 8,796,289; 9,051,327; 9,181,239; 9,714,244; 9 This includes inhibitors as described in U.S. Patent Publication Nos. 718,821; and 9,850,247; U.S. Patent Application Publication Nos. 20100113445 and 20160222459; and International Publication Nos. 2002090360, 2015019037, 2017013436, 2017216559, 2018011569, and 2018011570. Further Wee1 inhibitors include pyrazolopyrimidine derivatives, pyridopyrimidines, 4-(2-chlorophenyl)-9-hydroxypyrrolo[3,4-c]carbazole-1,3-(2H,6H)-dione (CAS No.: 622855-37-2), 6-butyl-4-(2-chlorophenyl)-9-hydroxypyrrolo[3,4-c]carbazole-1,3-(2H,6H)-dione (CAS No.: 62285550-9), 4-(2-phenyl)-9-hydroxypyrrolo[3,4-c]carbazole-1,3-(2H,6H)-dione (CAS No.: 1177150-89-8), and anti-Wee1 small interfering RNA (siRNA) molecules.

[0092] Exemplary DDRi-PARP inhibitors Another exemplary type of DDRi that may be used may be an inhibitor of poly(ADP-ribose) polymerase ("PARP"). Inhibitors of the DNA repair protein PARP (individually and collectively referred to as "PARPi") are approved for use in various solid tumors, such as breast and ovarian cancer, particularly in patients with BRCA1 / 2 mutations. BRCA1 and BRCA2 function in homologous recombination repair (HRR). Mutation induces genomic instability by altering the DNA repair process from a conservative and accurate HRR to a less faithful method, such as DNA end junctioning, which can lead to mutations through deletions and insertions. PARPi has been shown to induce synthetic lethality in BRCA1 / 2 mutant cells, as demonstrated by its potent monotherapy activity. This essentially involves blocking the repair of single-strand DNA breaks. Because HRR does not function in these tumor cells, cell death occurs. Since most tumors do not have BRCA1 or BRCA2 mutations, the efficacy of PARPi in such tumors is much lower.

[0093] To date, the FDA has approved four PARPi drugs (olaparib, niraparib, rucaparib, and talazoparib) as monotherapy, particularly for patients with germline and somatic mutations in the BRCA1 and BRCA2 genes. Along with veliparib, olaparib, niraparib, and rucaparib represent the first generation of PARPi drugs for which clinical trials have begun. Their IC50 values ​​are known to be in the nanomolar range. In contrast, second-generation PARPi drugs such as talazoparib have IC50 values ​​in the picomolar range. All of these PARPi enzymes, PARP1 and PARP2, have catalytic domains that bind to the binding site of the cofactor β-nicotinamide adenine dinucleotide (b-NAD+). The PARP family enzymes use NAD+ to covalently attach a poly(ADP-ribose) (PAR) chain to target proteins (a process called "PARization"). PARP1 (the most studied member) and PARP2 are key components of the DNA damage response (DDR) pathway. PARP1 is involved in the repair of single-strand DNA breaks and possibly other DNA damage (Woodhouse, et al.; Krishnakumar, et al.). PARP1 binds to damaged DNA via its zinc finger domain, then PAR-modifies a series of DNA repair effector proteins, releasing nicotinamide as a byproduct (Krishnakumar, et al.). Subsequently, self-PARization of PARP1 releases the protein from the DNA. However, available PARPi differ in their ability to capture PARP1 on DNA, and this appears to correlate with cytotoxicity and efficacy. Specifically, drugs such as talazoparib and olaparib are more effective at capturing PARP1 than veliparib (Murai, et al., 2012; Murai, et al., 2014).

[0094] The effectiveness of PARPi in ovarian and breast cancer patients with loss-of-function mutations in the BRCA1 or BRCA2 genes is largely due to the genetic concept of synthetic lethality. Specifically, BRCA1 and BRCA2 proteins normally maintain genomic integrity by mediating a DNA repair process known as homologous recombination repair (HRR). PARPi causes DNA damage that would normally be repaired by HR to persist. In the presence of PARPi, PARP1 is trapped on DNA, thereby halting the progression of the replication fork. This halt is cytotoxic unless repaired promptly by the HR system. Cells lacking effective HR cannot effectively repair this DNA damage and consequently die. Mutations in the BRCA gene and other HRR-related genes are still uncommon in many cancer types. Therefore, to further utilize the therapeutic effects of PARPi in such cancers, "artificial" synthetic lethality can be induced by combining PARPi with either chemotherapy or radiotherapy. Preclinical studies have demonstrated that the combination of radiotherapy and PARPi enhances the sensitivity of BRCA1 / 2 mutant tumor cells to PARP inhibition and improves the sensitivity of non-mutant BRCA tumors to PARP inhibition. Further studies have shown that ionizing radiation (IR) itself can mediate PARPi synthetic lethality in tumor cells. Therefore, an object of the present invention disclosed herein is to administer a radiolabeled HER3-targeted drug that delivers ionizing radiation in combination with PARPi.

[0095] In various embodiments of the present invention, PARPi may be a known drug that exhibits such a function, preferably an FDA-approved drug. Preferably, PARPi is olaparib (Lympalza®), niraparib (Zedura®), lucaparib (Rubraca®), or talazoparib (Talzena®). Clinically, PARPi therapy has demonstrated sustained antitumor effects in various cancers, including ovarian cancer, prostate cancer, pancreatic cancer, and triple-negative breast cancer (TNBC). In one clinical trial, TNBC patients with germline BRCA1 / 2 mutations were treated with the PARPi olaparib. This treatment showed a higher disease stabilization rate in BRCA1 / 2 mutation patients compared to non-mutated patients, but sustained responses were not achieved in any cohort (Gelmon, 2011). The inventors have found that the effects of PARPi can be improved by increasing dsDNA breaks induced by ionizing radiation from HER3-targeted drugs while the repair pathway is blocked by PARPi. Exemplary PARPi include olaparib, niraparib, rucaparib, and talazoparib.

[0096] E.CD47 blocker Additional agents administered in conjunction with HER3-targeted therapies may be CD47 blockers, for example, any agents that inhibit or reduce the activity and / or signaling between CD47 (e.g., on target cells) and SIRPα (e.g., on phagocytic cells) through interaction with CD47 or SIRPα. Non-limited examples of suitable CD4 blockers include CD47 and / or SIRPα reagents, non-limited to SIRPα polypeptides, anti-SIRPα antibodies, soluble CD47 polypeptides, and anti-CD47 antibodies or antibody fragments. Additional examples of CD47 blockers include agents that modulate the expression of CD47 and / or SIRPα. For example, such agents may include nucleic acid approaches such as phosphorodiamidate morpholino oligomers (PMOs) that block the translation of CD47, or human CD47-specific antibodies that modulate, e.g., block, suppress, reduce, antagonize, neutralize, or otherwise inhibit CD47 expression. CD47 antibodies or antisense approaches may suppress CD47 expression (e.g., suppress cell surface expression of CD47), activity, and / or signaling, or inhibit the interaction between CD47 and SIRPα. The agents provided herein, upon binding to or otherwise interacting with CD47, e.g., human CD47, completely or partially reduce or otherwise modulate the expression or activity of CD47. The reduction or modulation of the biological function of CD47 is carried out completely, significantly, or partially by the interaction between the antibody and the human CD47 polypeptide and / or peptide. A drug is considered to suppress CD47 expression or activity if the level of CD47 expression or activity in the presence of the antibody is reduced by at least 50%, for example, 60%, 70%, 80%, 90%, 95%, 96%, 98%, 99%, or 100%, compared to the level of CD47 expression or activity in the absence of interaction with the antibody described herein, for example, without binding.

[0097] In a particular embodiment, an anti-CD47 agent is an antibody that specifically binds to CD47 (i.e., an anti-CD47 antibody) and reduces the interaction between CD47 on one cell (e.g., an infected cell) and SIRPα on another cell (e.g., a phagocytic cell). Non-limiting examples of suitable antibodies include clones B6H12, 5F9, 8B6, and C3, as well as any antibodies described in International Publication No. 2011 / 143624 and U.S. Patent Application Publication No. 20210246206. Suitable anti-CD47 antibodies include fully human, humanized, or chimeric forms of such antibodies. Exemplary human antibodies or humanized antibodies that are particularly useful for in vivo applications in humans due to their low antigenicity include, at a minimum, monoclonal antibodies against CD47, such as Hu5F9-G4 (Sikic, et al. (2019) Journal of Clinical Oncology 37:946), a humanized monoclonal antibody available as maglorimab from Gilead; remzopalimab and TJC4 from I-Mab Biopharma; AO-176 from Arch Oncology, Inc; AK117 from Akesobio Australia Pty; IMC-002 from Innovent Biologics; ZL-1201 from Zia Lab; SHR-1603 from Jiangsu HengRui Medincine Co.; and SRF231 from Surface Oncology. Bispecific monoclonal antibodies that target both CD47 and PD-L1, such as IBI-322 from Innovent Biologics, are also available. Antibodies against SIRPα are also possible, such as Alx Oncology's ALX148; OSE's BI765063 (OSE-172); and small molecule inhibitors, such as EpicentRx's RRx-001 (1-bromoacetyl-3,3-dinitroazetidine) and azelnidipine (CAS number: 123524-52-7), or pharmaceutically acceptable salts thereof. See Table 4 for further exemplary drugs.

[0098] [Table 4]

[0099] In addition to inducing tumor phagocytosis by blocking the interaction between CD47 and SIRPα, AO-176 has been reported to preferentially bind to tumor cells rather than normal cells (especially RBCs, where binding is negligibly minimal), and to directly kill tumors more effectively than normal cells. Depending on the specific embodiment, the SIRPα reagent may contain a portion of SIRPα (typically located between the signal sequence and the transmembrane domain) sufficient to bind to CD47 with recognizable affinity, or fragments of these that retain binding activity. A suitable SIRPα reagent reduces (e.g., blocks, inhibits, etc.) the interaction between the native protein SIRPα and CD47. For example, CD47 blockers used in various embodiments of the present invention may be any of those disclosed in U.S. Patent No. 9,969,789, all of which include, but are not limited to, the SIRPα-IgG Fc fusion proteins disclosed in that patent, such as TTI-621 and TTI-622, which preferentially bind to CD47 on tumor cells and are also involved with the activated Fc receptor. For example, SIRPα-IgG Fc fusion proteins containing amino acid sequences SEQ ID NO: 116, SEQ ID NO: 117, or SEQ ID NO: 118 may be used.

[0100] The therapeutically effective dose of an anti-CD47 antibody or other CD47 protein inhibitor may be a dose that maintains a serum protein concentration of approximately 40 μg / mL or higher (for example, approximately 50 μg / mL or higher, approximately 60 μg / mL or higher, approximately 75 μg / mL or higher, approximately 100 μg / mL or higher, approximately 125 μg / mL or higher, or approximately 150 μg / mL or higher). The therapeutically effective dose or administration of CD47 blockers such as anti-CD47 antibodies, SIRPα fusion proteins, or small molecules is, for example, 0.05 to 10 mg / kg (drug mass / target body weight), for example, at least 0.1 mg / kg, 0.5 mg / kg, 1.0 mg / kg, 1.5 mg / kg, 2.0 mg / kg, 2.5 mg / kg, 3.0 mg / kg, 3.5 mg / kg, 4.0 mg / kg, 4.5 mg / kg, 5.0 mg / kg, 5.5 mg / kg, 6.0 mg / kg, 6.5 mg / kg, 7.0 mg / kg, 7.5 mg / kg kg, 8.0 mg / kg, 8.5 mg / kg, 9.0 mg / kg; or 10 mg / kg, 9.5 mg / kg, 9.0 mg / kg, 8.5 mg / kg, 8.0 mg / kg, 7.5 mg / kg, 7.0 mg / kg, 6.5 mg / kg, 6.0 mg / kg, 5.5 mg / kg, 5.0 mg / kg, 4.5 mg / kg, 4.0 mg / kg, 3.5 mg / kg, 3.0 mg / kg, 2.5 mg / kg, 2.0 mg / kg, 1.5 mg / kg, 1.0 mg / kg or less, or any combination of these upper and lower limits. The therapeutically effective doses of small molecule CD47 blockers, such as those disclosed herein, also include, for example, 0.01 to 1,000 mg / kg, and any sub-range or value of mg / kg within this range, for example, 0.01 to 500 mg / kg, or 0.05 to 500 mg / kg, or 0.5 to 200 mg / kg, or 0.5 to 150 mg / kg, or 1.0 to 100 mg / kg, or 10 to 50 mg / kg.

[0101] In a particular embodiment, an anti-CD47 agent is a soluble CD47 polypeptide that specifically binds to SIRPα and reduces the interaction between CD47 on one cell (e.g., an infected cell) and SIRPα on another cell (e.g., a phagocytic cell). A suitable soluble CD47 polypeptide can bind to SIRPα without activating or stimulating SIRPα signaling, since SIRPα activation inhibits phagocytosis. Instead, a suitable soluble CD47 polypeptide promotes preferential phagocytosis of infected cells over uninfected cells. These cells (e.g., infected cells) expressing high levels of CD47 compared to normal non-target cells (normal cells) will be preferentially phagocytosed. Thus, a suitable soluble CD47 polypeptide specifically binds to SIRPα without activating / stimulating sufficient signaling responses to inhibit phagocytosis. In some cases, a suitable soluble CD47 polypeptide may be a fusion protein (e.g., as described in U.S. Patent No. 20100239579). Advantageously, CD47 blockers can enhance the cytotoxic and phagocytic effects of radiolabeled targeted drugs, such as radiolabeled HER3 and / or HER2 targeted drugs, while reducing the dose-limiting radiotoxicity of the targeted drugs, thereby improving the tolerability of the targeted drugs used / accepted in the treatment of the target and enabling higher radiation doses. [Examples]

[0102] Preparation of radiolabeled HER3-targeted drugs HER3-targeted drugs, such as monoclonal antibodies against HER3, can be prepared using indium-111 in accordance with the procedures detailed in International Publication No. 2017 / 155937 and U.S. Provisional Patent Application No. 63 / 042651, entitled "Compositions and methods for preparation of site-specific radioconjugates," filed on December 9, 2019. 111 In) or Actinium-225 ( 225 It can be labeled with Ac).

[0103] radioactive labelFor example, an antibody may be conjugated to a chelating agent-containing linker as described herein or in the aforementioned patent application. An exemplary linker is at least dodecanetetraacetic acid (DOTA), and the purpose of the conjugation reaction is to achieve a DOTA:antibody ratio of 3:1 to 5:1. Then, the radionuclide... 111 In or 225 Chelation was carried out using Ac, and the obtained 111 In or 225 The efficacy and purity of Ac-labeled anti-HER3 antibodies can be determined by HPLC and iTLC. 225 An example labeling reaction for Ac is as follows: In the reaction, 15 μL of 0.15 M NH4OAc buffer (pH=6.5) and 2 μL (10 μg) of DOTA-anti-HER3 (5 mg / mL) are mixed in an Eppendorf reaction tube, followed by 4 μL (10 μCi) in 0.05 M HCl 225 Ac may be added. The contents of the tube are mixed at the tip of the pipette, and the reaction mixture can be incubated at 37°C for 90 minutes with shaking at 100 rpm. At the end of the incubation time, 3 μL of 1 mM DTPA solution is added to the reaction mixture and incubated at room temperature for 20 minutes for any unreacted mixture. 225 By bonding Ac, 225 Ac-DTPA complexes can be formed. Immediate thin-layer chromatography using a 10 cm silica gel strip and a 10 mM EDTA / saline mobile phase was performed. 225 Ac-labeled anti-HER3 ( 225 Ac-DOTA (anti-HER3) release 225 Ac( 225 By separating it from Ac-DTPA, 225 The radiochemical purity of Ac-DOTA-anti-HER3 can be determined. In this system, the radiolabeled antibody remains at the application site. 225 Ac-DTPA moves along with the solvent tip. Cut the strip in half and use a gamma counter equipped with a multichannel analyzer. 225 The nuclei can be counted using channels 72-110 for Ac, and their daughter nuclei can be excluded.

[0104] purification: An exemplary radiolabeled HER3-targeted drug, for example 225 Ac-DOTA-anti-HER3 can be purified using a PD10 column pre-blocked with 1% HSA, or in a Vivaspin centrifuge with a fractional molecular weight of 50 kDa, washing twice with 1.5 mL and circulating for 3 minutes / rotation. 225 HPLC analysis of Ac-DOTA-anti-HER3 can be performed using a Waters HPLC system equipped with flow-through Waters UV and Bioscan radiation detectors, with a TSK3000SW XL column eluted with PBS at pH=7.4 and a flow rate of 1 mL / min. Stability measurements : 225 Exemplary radiolabeled HER3-targeted drugs such as Ac-DOTA-anti-HER3 may be used for stability measurements. 225 Ac-DOTA-anti-HER3 can be tested in its original volume or diluted (2-10 times) with working buffer (0.15 M NH4OAc), incubated at room temperature (rt) for 48 hours or at 4°C for 96 hours, and then tested by ITLC. Stability is measured by comparing with untreated radiolabeled anti-HER3 before and after incubation. 225 Other antibodies labeled with Ac have been shown to be stable at 4°C for up to 96 hours. Immunoreactivity (IR) measurement : 225 Exemplary radiolabeled HER3-targeted drugs, such as Ac-DOTA-anti-HER3, can be used in immunoreactivity studies. HER3-positive and control HER3-negative cells may be used in quantities of 1 to 7.5 million cells per sample to examine binding levels (percentage of radioactivity binding to cells after several washes; or an immunoreactive portion (IRF) bead assay may be used according to the method disclosed in Sharma, 2019). 111 In or 225 Previous assays using other antibodies radiolabeled with Ac showed an immunoreactivity of approximately 50-60%. [Examples]

[0105] Exemplary PARPi administration and administration regimens (A) Olaparib (Lympalza®) - Standard and reduced dose regimens Olaparib is marketed by AstraZeneca under the trademark name Lymphalza®. Lymphalza® is marketed in 100 mg and 150 mg tablet forms. The dosage is 300 mg orally twice daily, for a total daily dose of 600 mg. Administration is continued until disease progression or unacceptable toxicity occurs. This dosing regimen, regardless of the disease being treated, is referred to herein as the “normal” human dosing regimen for Lymphalza®. Any dosing regimen of a shorter duration (e.g., 21 days) or with a lower dose of Lymphalza® (e.g., 300 mg / day) is referred to herein as a “reduced-dose” human dosing regimen. Examples of reduced-dose human administration regimens include: (i) 550 mg / day; (ii) 500 mg / day; (iii) 450 mg / day; (iv) 400 mg / day; (v) 350 mg / day; (vi) 300 mg / day; (vii) 250 mg / day; (viii) 200 mg / day; (ix) 150 mg / day; (x) 100 mg / day; or (xi) 50 mg / day.

[0106] (B) Niraparib (Zejula®) - Standard and reduced dose regimens Niraparib is marketed by Tesaro under the trademark name Zejura®. Zejura® is marketed in 100 mg capsule form. The dosage is 300 mg orally once daily. Administration should be continued until disease progression or an unacceptable adverse reaction occurs. This dosing regimen, regardless of the disease being treated, is referred to herein as the “normal” human dosing regimen of Zejura®. Any dosing regimen of a shorter duration (e.g., 21 days) or with a lower dose of Zejura® (e.g., 150 mg / day) is referred to herein as a “reduced-dose” human dosing regimen. Examples of reduced-dose human dosing regimens include: (i) 250 mg / day; (ii) 200 mg / day; (iii) 150 mg / day; (iv) 100 mg / day; or (v) 50 mg / day.

[0107] (C) Lucaparib (Rubraca®) - Standard and reduced dose regimens Lucaparib is marketed under the trademark name Rubraca® by Clovis Oncology, Inc. Rubraca® is available in 200 mg and 300 mg tablets. The dosage is 600 mg orally twice daily, for a total daily dose of 1,200 mg. Treatment is continued until disease progression or unacceptable toxicity occurs. This dosing regimen, regardless of the disease being treated, is referred to herein as the “normal” human dosing regimen for Rubraca®. Any dosing regimen of a shorter duration (e.g., 21 days) or with a lower dose of Rubraca® (e.g., 600 mg / day) is referred to herein as a “reduced-dose” human dosing regimen. Examples of dose reduction regimens for humans include: (i) 1,150 mg / day; (ii) 1,100 mg / day; (iii) 1,050 mg / day; (iv) 1,000 mg / day; (v) 950 mg / day; (vi) 900 mg / day; (vii) 850 mg / day; (viii) 800 mg / day; (ix) 750 mg / day; (x) 700 mg / day; (xi) 65 0 mg / day; (xii) 600 mg / day; (xiii) 550 mg / day; (xiv) 500 mg / day; (xv) 450 mg / day; (xvi) 400 mg / day; (xvii) 350 mg / day; (xviii) 300 mg / day; (xix) 250 mg / day; (xx) 200 mg / day; (xxi) 150 mg / day; or (xxii) 100 mg / day.

[0108] (D) Talazoparib (Talzena®) - Standard and reduced dose regimens Talazoparib is marketed by Pfizer Labs under the trademark name Talzena®. Talzena® is marketed in 1 mg capsule form. The dosage is 1 mg orally. Administration is continued until disease progression or unacceptable toxicity occurs. This dosing regimen, regardless of the disease being treated, is referred to herein as the “normal” human dosing regimen for Talzena®. Any dosing regimen of a shorter duration (e.g., 21 days) or with a lower dose of Talzena® (e.g., 0.5 mg / day) is referred to herein as a “reduced-dose” human dosing regimen. Examples of reduced-dose human administration regimens include: (i) 0.9 mg / day; (ii) 0.8 mg / day; (iii) 0.7 mg / day; (iv) 0.6 mg / day; (v) 0.5 mg / day; (vi) 0.4 mg / day; (vii) 0.3 mg / day; (viii) 0.2 mg / day; or (ix) 0.1 mg / day. [Examples]

[0109] HER3-targeted drug and PARPi administration regimen Human patients may be treated according to the following regimen: Orally administer one of olaparib, niraparib, rucaparib, or talazoparib (PARPi) according to one of the administration regimens described in Example 2, in combination with intravenous administration of a radiolabeled HER3-targeted drug as detailed herein, either as a single dose or in divided doses. For example, the following are examples of administration regimens: (a) PARPi and HER3-targeted drugs are administered simultaneously, (i) starting on the same day, (ii) the HER3-targeted drug is administered as a single dose or in divided doses at intervals of one week or more, and (iii) PARPi is administered once or twice daily (as needed) for the same period as or longer than the administration of the HER3-targeted drug; or (b) PARPi and HER3-targeted drugs are administered simultaneously, (i) PARPi is administered at least one week before the administration of the HER3-targeted drug, (ii) the HER3-targeted drug is administered as a single dose or in divided doses at intervals of one week or more, and (iii) PARPi is administered once or twice daily (as needed) for the same period as or longer than the administration of the HER3-targeted drug. [Examples]

[0110] HER3-targeted drug and CD47-blocker administration regimen According to certain aspects of the present invention, a CD47 blocker may be, for example, a monoclonal antibody that prevents CD47 from binding to SIRPα. Exemplary protein CD47 blockers include maglorimab, remzopalimab, AO-176, TTI-621, TTI-622, or combinations thereof. Alternatively or additionally, CD47 blockers may include agents that modulate the expression of CD47 and / or SIRPα, such as phosphorodiamidate morpholino oligomers (PMOs) that inhibit the translation of CD47, e.g., MBT-001 (PMO (morpholino) sequence: 5'-CGTCACAGGCAGGACCCACTGCCCA-3') [SEQ ID NO: 114]), or any of the PMO oligomer CD47 inhibitors described in any of U.S. Patents 8,557,788, 8,236,313, 10,370,439, and International Publication No. 2008060785. The therapeutically effective dose of anti-CD47 antibody contains at least 0.05 to 10 mg / kg. Accordingly, the method of the present invention may involve administering one or more anti-CD47 antibodies or other agents in a single or divided dose, in combination with intravenous administration of a radiolabeled HER3-targeted drug as detailed herein. For example, the following are examples of administration regimens: (a) simultaneous administration of an anti-CD47 antibody or anti-CD47 drug and a HER3-targeted drug, (i) starting administration of each from the same day, (ii) the HER3-targeted drug as a single dose or in divided doses with an interval of one week or more, and (iii) the anti-CD47 antibody or anti-CD47 drug administered once or twice daily (as needed) for the same period as or longer than the administration of the HER3-targeted drug; or (b) simultaneous administration of an anti-CD47 antibody or anti-CD47 drug and a HER3-targeted drug, (i) administration of the anti-CD47 antibody or anti-CD47 drug at least one week before administration of the HER3-targeted drug, (ii) the HER3-targeted drug administered as a single dose or in divided doses with an interval of one week or more, and (iii) the anti-CD47 antibody or anti-CD47 drug administered once or twice daily (as needed) for the same period as or longer than the administration of the HER3-targeted drug.

Example

[0111] HER3 Targeting Agent and ICI Administration Regimen According to certain aspects of the present invention, the immune checkpoint inhibitor (ICI) can be a monoclonal antibody against any of PD-1, PD-L1, PD-L2, CTLA-4, CD137. The therapeutically effective doses of these antibodies include at least 0.05 - 10 mg / kg. Thus, the method of the present invention includes administering one or more ICIs in either single or divided doses in combination with intravenous administration of a radiolabeled HER3 targeting agent detailed herein. For example, examples of administration regimens are as follows: (a) simultaneously administering an ICI and a HER3 targeting agent, (i) each administered on the same day, (ii) the HER3 targeting agent is administered as a single dose or divided doses at intervals of one week or more, and (iii) the ICI is administered once or twice a day (if necessary) over the same or longer period as the administration of the HER3 targeting agent; or (b) simultaneously administering an ICI and a HER3 targeting agent, (i) the anti-CD47 antibody is administered at least one week before the administration of the HER3 targeting agent, (ii) the HER3 targeting agent is administered as a single dose or divided doses at intervals of one week or more, and (iii) the ICI is administered once or twice a day (if necessary) over the same or longer period as the administration of the HER3 targeting agent.

[0112] Non-limitingly, the present disclosure also provides the following aspects. Aspect 1: A method of treating solid cancer in a mammalian subject such as a human, the method comprising administering a therapeutically effective amount of a radiolabeled HER3 targeting agent to the subject. Aspect 2: The method according to any one of the preceding aspects, wherein the solid cancer is breast cancer, gastric cancer, bladder cancer, cervical cancer, endometrial cancer, skin cancer, gastric cancer, testicular cancer, esophageal cancer, bronchioloalveolar carcinoma, prostate cancer, colorectal cancer, ovarian cancer, cervical squamous cell carcinoma, pancreatic cancer, lung cancer, kidney cancer, head and neck cancer, or any combination thereof. Aspect 3: The method according to any one of the preceding aspects, wherein the solid cancer is colorectal cancer, gastric cancer, ovarian cancer, non-small cell lung cancer, head and neck squamous cell cancer, pancreatic cancer, renal cancer, or any combination thereof. Aspect 4: The method according to any one of the preceding aspects, wherein the solid cancer is a HER3-positive cancer such as a HER3-positive solid tumor. Aspect 5: The radiolabeled HER3 targeting agent is 131 I, 125 I, 123 I, 90 Y, 177 Lu, 186 Re, 188 Re, 89 Sr, 153 Sm, 32 P, 225 Ac, 213 Bi, 213 Po, 211 At, 212 Bi, 213 Bi, 223 Ra, 227 Th, 149 Tb, 137 Cs, 212 Pb, 103 Pd, or a radiolabel selected from any of those disclosed herein, or any combination thereof, in the method according to any one of the preceding aspects.

[0113] Aspect 6: The HER3 targeting agent is 131 I, 90 Y, 177 Lu, 225 Ac, 213 Bi, 211 At, 213 Bi, 227 Th, 212 Pb, or a radiolabel selected from any combination thereof, in the method according to any one of the preceding aspects. Aspect 7: The method according to any one of the preceding aspects, wherein the radiolabeled HER3 targeting agent comprises an antibody against HER3. Embodiment 8: The method according to any one of the embodiments described herein, wherein the HER3-targeted drug comprises an anti-HER3 monoclonal antibody such as any of those disclosed herein, for example, a HER3 antibody selected from patritumab, cerivanthumab (MM-121), lumuretuzumab, elgemtumab, GSK2849330, and AV-203, and any combination thereof. Embodiment 9: The method according to any one of the embodiments described above, wherein the HER3-targeting drug comprises (i) a heavy chain sequence including SEQ ID NO: 77 and / or a light chain sequence including SEQ ID NO: 78; (ii) an immunoglobulin heavy chain variable region including CDR-H1 including SEQ ID NO: 15, CDR-H2 including SEQ ID NO: 16, and / or CDR-H3 including SEQ ID NO: 17, and / or an immunoglobulin light chain variable region including CDR-L1 including SEQ ID NO: 18, CDR-L2 including SEQ ID NO: 19, and / or CDR-L3 including SEQ ID NO: 20; (iii) an immunoglobulin heavy chain variable region including SEQ ID NO: 21 and / or an immunoglobulin light chain variable region including SEQ ID NO: 22; or (iv) a monoclonal antibody having the immunoglobulin heavy chain amino acid sequence of SEQ ID NO: 23 and / or the immunoglobulin light chain amino acid sequence of SEQ ID NO: 24. Embodiment 10: The method according to any one of the embodiments described above, wherein the HER3-targeting drug comprises a monoclonal antibody having a heavy chain variable region having the amino acid sequence specified in SEQ ID NO: 7 and / or a light chain variable region having the amino acid sequence specified in SEQ ID NO: 8.

[0114] Embodiment 11: The method according to any one of the embodiments described above, wherein the HER3-targeting drug comprises one or more heavy chain N-terminal regions and complementarity-determining regions (CDRs) having the amino acid sequences specified in SEQ ID NO: 13 and / or 1 to 3, respectively; and / or a monoclonal antibody comprising one or more light chain N-terminal regions and CDRs having the amino acid sequences specified in SEQ ID NO: 14 and / or 4 to 6, respectively. Embodiment 12: The method according to any one of the embodiments described above, wherein the effective dose of the radiolabeled HER3-targeted drug is the maximum tolerated dose. Embodiment 13: Radiolabeled HER3-targeted drugs are225 Ac, 177 Lu, or 131 The method according to any one of the above embodiments, which is labeled with I. Embodiment 14: The method according to any one of the embodiments described above, wherein the therapeutic effective dose of the radiolabeled HER3-targeted drug is less than 2 Gy or less than 8 Gy, for example, a single dose delivered to a target dose of 2 to 8 Gy. Appearance 15: Radiolabeled HER3 target drug is 225 It is marked with Ac, 225 The method according to any one of the above embodiments, wherein the effective dose of the Ac-labeled HER3 target drug includes a dose of 0.1 to 50 μCi / kg target body weight, or 0.2 to 20 μCi / kg target body weight, or 0.5 to 10 μCi / kg target body weight.

[0115] Embodiment 16: Radiolabeled HER3-targeted drugs are 225 This is a full-length antibody against HER3 labeled with Ac, 225 The method according to any one of the above embodiments, wherein the effective dose of the Ac-labeled HER3 target drug is less than 5 μCi / kg of body weight, for example, including 0.1 to 5 μCi / kg of body weight. Embodiment 17: Radiolabeled HER3-targeted drugs are 225 Antibody fragments against HER3 labeled with Ac, such as minibodies or nanobodies, 225 The method according to any one of the above embodiments, wherein the effective dose of the Ac-labeled HER3 target drug is greater than 5 μCi / kg of target body weight, for example, 5 to 20 μCi / kg of target body weight. Apparatus 18: Radiolabeled HER3 target drug is 225 It is marked with Ac, 225 The method according to any one of embodiments 1 to 14, wherein the effective dose of the Ac-labeled HER3 target drug comprises 2 μCi to 2 mCi, or 2 to 250 μCi, or 75 to 400 μCi. Appearance 19: Radioisotope-labeled HER3-targeted drugs are 177The method according to any one of embodiments 1 to 14, wherein the HER3-targeting drug is labeled with Lu, and the effective dose of the HER3-targeting drug includes doses less than 1000 μCi / kg target body weight, for example, doses of 1 to 900 μCi / kg target body weight, or 5 to 250 μCi / kg target body weight, or 50 to 450 μCi / kg target body weight. Apparatus 20: Radioisotope-labeled HER3-targeted drugs are 177 It is marked with Lu, 177 The method according to any one of embodiments 1 to 14, wherein the effective dose of the Lu-labeled HER3 target drug includes a dose of 10 to 30 mCi or less, or at least 100 μCi to 3 mCi or less, or 3 to 30 mCi or less.

[0116] Embodiment 21: Radiolabeled HER3 target drug is 131 It is marked with I, 131 The method according to any one of embodiments 1 to 14, wherein the effective dose of the I-labeled HER3-targeted drug includes doses of less than 1200 mCi, for example, doses of 25 to 1200 mCi, or 100 to 400 mCi, or 300 to 600 mCi, or 500 to 1000 mCi. Embodiment 22: Radiolabeled HER3 target drug is 131 It is marked with I, 131 The method according to any one of embodiments 1 to 14, wherein the effective dose of the I-labeled HER3-targeted drug includes doses of less than 200 mCi, for example, doses of 1 to 200 mCi, or 25 to 175 mCi, or 50 to 150 mCi. Embodiment 23: The method according to any one of the embodiments described above, wherein the effective dose of the HER3-targeted drug is less than 3 mg / kg of target body weight, for example, 0.001 to 3.0 mg / kg of patient body weight, or 0.005 to 2.0 mg / kg of patient body weight, or 0.01 to 1 mg / kg of patient body weight, or 0.1 to 0.6 mg / kg of patient body weight, or 0.3 mg / kg of patient body weight, or 0.4 mg / kg of patient body weight, or 0.5 mg / kg of patient body weight, or 0.6 mg / kg of patient body weight, comprising a protein dose. Embodiment 24: The method according to any one of the embodiments described above, wherein the HER3-targeted drug is administered over the course of treatment according to a dosing schedule selected from the group consisting of once every 7, 10, 12, 14, 20, 24, 28, 35, and 42 days, and the total number of doses during the course of treatment is at least two. Embodiment 25: The method according to any one of Embodiments 1 to 6, wherein the HER3 target drug is a peptide or a small molecule.

[0117] Embodiment 26: The method according to any one of the embodiments described above, further comprising administering a therapeutically effective dose of an immune checkpoint drug, a chemotherapeutic agent, a DNA damage response inhibitor (DDRi), a CD47 blocker, or a combination thereof to a target. Embodiment 27: The method according to Embodiment 26, wherein the immune checkpoint therapeutic agent comprises an antibody or other blocking agent against CTLA-4, PD-1, TIM-3, VISTA, BTLA, LAG-3, TIGIT, CD28, OX40, GITR, CD137, CD40, CD40L, CD27, HVEM, PD-L1, PD-L2, PD-L3, PD-L4, CD80, CD86, CD137-L, GITR-L, CD226, B7-H3, B7-H4, BTLA, TIGIT, GALS, KIR, 2B4, CD160, or CGEN-15049, or any combination of such antibodies and blocking agents. Embodiment 28: The method according to Embodiment 27, wherein the immune checkpoint therapeutic agent comprises antibodies against PD-1, PD-L1, PD-L2, CTLA-4, CD137, or a combination thereof. Embodiment 29: The method according to Embodiment 26, wherein DDRi comprises a poly(ADP-ribose) polymerase inhibitor (PARPi), ataxia telangiectasia mutation inhibitor (ATMi), ataxia telangiectasia mutation and Rad3-related inhibitor (ATRi), or a Wee1 inhibitor. Embodiment 30: The method according to Embodiment 29, wherein PARPi comprises one or more of olaparib, niraparib, lucaparib, and thalazoparib.

[0118] Embodiment 31: The method according to Embodiment 29, wherein ATMi comprises one or more of KU-55933, KU-59403, Waltmannin, CP466722, or KU-60019. Embodiment 32: The method according to Embodiment 29, wherein ATRi comprises one or more of cisandrin B, NU6027, NVP-BEA235, VE-821, VE-822, AZ20, or AZD6738. Embodiment 33: The method according to Embodiment 29, wherein the Wee1 inhibitor comprises AZD-1775 (i.e., adavocertib). Embodiment 34: The method according to Embodiment 29, wherein the CD47 blocker includes a drug such as a monoclonal antibody that prevents CD47 from binding to SIRPα, and / or a drug that modulates CD47 expression. Embodiment 35: The method according to Embodiment 34, wherein the CD47 blocker comprises one or more of maglorimab, remzopalimab, AO-176, TTI-621, TTI-622, or a combination thereof; and / or the agent modulating CD47 expression comprises a phosphorodiamidate morpholino oligomer (PMO) (e.g., MBT-001) that reduces CD47 expression.

[0119] Embodiment 36: The method according to Embodiment 34, wherein the therapeutically effective dose of the CD47 blocker includes 0.05 to 5 mg / kg patient body weight. Embodiment 37: The method according to Embodiment 26, wherein a HER3-targeted drug is administered at least one week before an immune checkpoint drug and / or a DDRi and / or a CD47 blocker; or an immune checkpoint drug and / or a DDRi and / or a CD47 blocker is administered at least one week before a HER3-targeted drug. Embodiment 38: The method according to Embodiment 26, wherein a HER3-targeted drug is administered together with one of an immune checkpoint drug, a DDRi, or a CD47 blocker, and the other of the immune checkpoint drug, DDRi, or CD47 blocker is administered either before or after the HER3-targeted drug. Embodiment 39: The method according to Embodiment 26, wherein a HER3-targeted drug is administered simultaneously with an immune checkpoint therapy drug and / or a DDRi and / or a CD47 blocker. Embodiment 40: The method according to any one of the embodiments described above, wherein the HER3 target drug is a polyspecific antibody, and the polyspecific antibody comprises a first target recognition component that specifically binds to an epitope of HER3, and a second target recognition component that specifically binds to an epitope of HER3 different from the first target recognition component or to an epitope of a different antigen.

[0120] Embodiment 41: The method according to Embodiment 40, wherein the HER3-targeting agent comprises a bispecific antibody against HER3 / HER2, e.g., MM-111 or MCLA0-128, or a bispecific antibody against IGF-1R / HER3, e.g., MM-141 (i.e., istilatumab), and / or a bispecific antibody against HER1 / HER3, e.g., MEHD7945A (i.e., durigotumab). Embodiment 42: A method for treating a proliferative disorder or impairment, comprising diagnosing a subject having HER3-positive cells, and, if the subject has HER3-positive cells, administering a therapeutically effective dose of a HER3-targeted drug to the subject according to any one of the methods of Embodiments 1 to 41. Embodiment 43: Diagnosis includes collecting a blood or tissue sample of the subject; placing the sample on a substrate; and detecting the presence or absence of the HER3 antigen using a diagnostic antibody, wherein the diagnostic antibody is radiolabeled, for example, 3 H, 14 C, 32 P, 35 S, and 1257 I; the method according to embodiment 42, comprising a fluorescent or chemiluminescent compound, for example, fluorescein isothiocyanate, rhodamine, or luciferin; or an antibody against HER3 labeled with an enzyme, for example, alkaline phosphatase, β-galactosidase, or horseradish peroxidase. Appearance 44: To diagnose, the HER3-targeted drug is 18 F, 11 C, 68 Ga, 64 Cu, 89 Zr, 124 I, 99m Tc, or 111The method according to aspect 42, comprising: administering a HER3-targeted drug containing a radiolabel selected from the group including In; waiting for a sufficient amount of time to allow the HER3-targeted drug to accumulate in the tissue site; and imaging the tissue using non-invasive imaging techniques to detect the presence or absence of HER3-positive cells. Aspect 45: Non-invasive imaging techniques are, 18 F, 11 C, 68 Ga, 64 Cu, 89 Zr, or 124 Positron emission tomography (PET imaging) for HER3-labeled 1-I drugs, or 99m Tc or 111 The method according to aspect 44, comprising single-photon emission tomography (SPECT imaging) for an In-labeled HER3-targeted drug.

[0121] While various specific embodiments have been illustrated and described herein, it will be understood that various modifications can be made without departing from the spirit and scope of the invention. Furthermore, features described in relation to one aspect of the invention may be used in combination with other aspects of the invention, even if such combinations are not explicitly illustrated.

[0122] [References] TIFF2023550462000005.tif104166

Claims

1. A radiopharmaceutical composition comprising a therapeutically effective amount of a radionuclide-labeled HER3 targeted drug for treating a solid tumor in a mammalian subject.

2. The radionuclide labeled HER3 targeted drug comprises: 131 I, 125 I, 123 I, 90 Y. 177 Lu, 186 Re, 188 Re, 89 Sr, 153 Sm, 32 P. 225 Ac, 213Po, 211 At, 212 Bi, 213 Bi, 223 Ra, 227 Th, 149 Tb, 137 Cs, 212 Pb, or 103 2. The radiopharmaceutical composition of claim 1, comprising a radiolabel selected from the group consisting of Pd, Pd, and combinations thereof.

3. The radionuclide labeled HER3 targeted drug comprises: 225 A c, 177 Lu, 131 I, 90 Y, 211At, 212Bi, 213 Bi, 227 Th, 212 4. The radiopharmaceutical composition of claim 1, comprising a radiolabel selected from the group consisting of , ...

4. 2. The radiopharmaceutical composition of claim 1, wherein said radionuclide-labeled HER3 targeted drug comprises a humanized antibody against HER3.

5. 2. The radiopharmaceutical composition of claim 1, wherein said radionuclide labeled HER3 targeted drug comprises one or more of patritumab, seribantumab, lumuletuzumab, elgemtumab, GSK2849330, CDX-3379, ISU104, HMBD-001 (10D1F), REGN1400, and AV203.

6. 2. The radiopharmaceutical composition of claim 1, wherein the radionuclide-labeled HER3 targeted drug comprises a monoclonal antibody comprising one or both of a heavy chain sequence comprising SEQ ID NO:77 and a light chain sequence comprising SEQ ID NO:

78.

7. The radionuclide labeled HER3 targeted drug comprises: (i) (a) an immunoglobulin heavy chain variable region comprising CDR-H1 comprising SEQ ID NO: 15, CDR-H2 comprising SEQ ID NO: 16, and / or CDR-H3 comprising SEQ ID NO: 17; and (b) an immunoglobulin light chain variable region comprising CDR-L1 comprising SEQ ID NO: 18, CDR-L2 comprising SEQ ID NO: 19, and / or CDR-L3 comprising SEQ ID NO: 20; One or both of the following: (ii) one or both of an immunoglobulin heavy chain variable region comprising SEQ ID NO:21 and an immunoglobulin light chain variable region comprising SEQ ID NO:22; or (iii) one or both of the immunoglobulin heavy chain amino acid sequence of SEQ ID NO: 23 and the immunoglobulin light chain amino acid sequence of SEQ ID NO: 24 2. The radiopharmaceutical composition of claim 1 comprising a monoclonal antibody comprising:

8. 2. The radiopharmaceutical composition of claim 1, wherein said radionuclide labeled HER3 targeted drug is a monoclonal antibody comprising a heavy chain having a complementarity determining region (CDR) having the amino acid sequence as set forth in SEQ ID NO: 13 and / or 1-3, respectively; and / or a light chain having a CDR having the amino acid sequence as set forth in SEQ ID NO: 14 and / or 4-6, respectively.

9. 2. The radiopharmaceutical composition of claim 1, wherein the solid cancer is breast cancer, gastric cancer, bladder cancer, cervical cancer, endometrial cancer, skin cancer, stomach cancer, testicular cancer, esophageal cancer, bronchioloalveolar carcinoma, prostate cancer, colorectal cancer, ovarian cancer, cervical epidermoid carcinoma, pancreatic cancer, lung cancer, renal cancer, head and neck cancer, or any combination thereof.

10. The radiopharmaceutical composition of claim 1 , wherein the solid cancer is breast cancer, gastric cancer, pancreatic cancer, or any combination thereof.

11. The radiopharmaceutical composition of claim 1 , wherein the solid tumor comprises a HER3 positive cancer cell.

12. 2. The radiopharmaceutical composition of claim 1, wherein the effective amount of said radionuclide-labeled HER3 targeted drug is the maximum tolerated dose.

13. The radionuclide-labeled HER3 targeted drug 225 is labeled with Ac, 225 2. The radiopharmaceutical composition of claim 1, wherein the effective amount of Ac-labeled HER3 targeted drug comprises a dose of 0.1-50 μCi / kg of subject body weight, or 0.1-5 μCi / kg of subject body weight, or 5-20 μCi / kg of subject body weight.

14. The radionuclide-labeled HER3 targeted drug 225 is labeled with Ac, 225 2. The radiopharmaceutical composition of claim 1, wherein the effective amount of Ac-labeled HER3 targeted drug comprises a dose of 2 μCi to 2 mCi, or 2 μCi to 250 μCi, or 75 μCi to 400 μCi.

15. 2. The radiopharmaceutical composition of claim 1, wherein the effective amount of said radionuclide labelled HER3 targeted drug comprises a protein dosage of less than 3 mg / kg subject body weight, for example from 0.001 mg / kg patient body weight to 3.0 mg / kg patient body weight, or from 0.005 mg / kg patient body weight to 2.0 mg / kg patient body weight, or from 0.01 mg / kg patient body weight to 1 mg / kg patient body weight, or from 0.1 mg / kg patient body weight to 0.6 mg / kg patient body weight, or from 0.3 mg / kg patient body weight, or from 0.4 mg / kg patient body weight, or from 0.5 mg / kg patient body weight, or from 0.6 mg / kg patient body weight.

16. 2. The radiopharmaceutical composition of claim 1, wherein said radionuclide-labeled HER3 targeted drug is administered according to a dosing schedule selected from the group consisting of once every 7, 10, 12, 14, 20, 24, 28, 36, and 42 days over a treatment period, comprising at least two administrations during said treatment period.

17. 2. The radiopharmaceutical composition of claim 1, further comprising administering to the subject a therapeutically effective amount of an immune checkpoint therapeutic, a DNA damage response inhibitor (DDRi), a CD47 blocking agent, a chemotherapeutic agent, or a combination thereof.

18. 18. The radiopharmaceutical composition of claim 17, wherein said immune checkpoint therapeutic comprises an antibody against PD-1, PD-L1, PD-L2, CTLA-4, CD137, or a combination thereof.

19. 18. The radiopharmaceutical composition of claim 17, wherein said DDRi comprises a poly(ADP-ribose) polymerase inhibitor (PARPi), an ataxia telangiectasia mutated inhibitor (ATMi), an ataxia telangiectasia mutated and Rad3 associated inhibitor (ATRi), or a Wee1 inhibitor.

20. 2. The radiopharmaceutical composition of claim 1, wherein said radionuclide-labeled HER3 targeted drug is also specific for HER2.

21. 21. The radiopharmaceutical composition of claim 1 or 20, wherein the radiolabelled HER3 targeted drug comprises a chemically conjugated chelator group that chelates a radionuclide.

22. 22. The radiopharmaceutical composition of claim 21 , wherein the chelator group comprises DOTA.

23. A radiopharmaceutical composition according to any one of claims 1 to 22, comprising a radioactively labeled portion of a HER3 targeted drug and a non-radioactively labeled portion of a HER3 targeted drug.

24. The radiopharmaceutical composition of claim 23, further comprising at least one pharma- ceutically acceptable excipient.

25. A radiopharmaceutical composition for use after diagnosing the subject with HER3-positive cancer.

26. The radiopharmaceutical composition of claim 25, wherein diagnosing the subject comprises imaging HER3 positive cells in the subject using a radionuclide-labeled HER3 targeted drug.